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Abstract 
Objective: The objective is to formulate clinical practice guidelines for hormonal replacement in 
hypopituitarism in adults. 
 
Participants: The participants include an Endocrine Society-appointed Task Force of six experts, a 
methodologist, and a medical writer. The American Association for Clinical Chemistry, The Pituitary 
Society, and the European Society of Endocrinology co-sponsored this guideline. 
  
Evidence: The Task Force developed this evidence-based guideline using the Grading of 
Recommendations, Assessment, Development, and Evaluation system to describe the strength of 
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recommendations and the quality of evidence. The Task Force commissioned two systematic reviews and 
used the best available evidence from other published systematic reviews and individual studies. 
 
Consensus Process: One group meeting, several conference calls, and e-mail communications enabled 
consensus. Committees and members of the Endocrine Society, the American Association for Clinical 
Chemistry, The Pituitary Society, and the European Society of Endocrinology reviewed and commented 
on preliminary drafts of these guidelines.   
 
Conclusions: Using an evidence-based approach, this guideline addresses important clinical issues 
regarding the evaluation and management of hypopituitarism in adults, including appropriate biochemical 
assessments; specific therapeutic decisions to decrease the risk of co-morbidities due to hormonal over-
replacement or under-replacement; and managing hypopituitarism during pregnancy, pituitary surgery, 
and other types of surgeries. 
 
Number of Words, Tables, and Figures 
Word Count: Document 14,298; Abstract, 197; Tables: 6; Figures: 0; Appendix: 1 
Abbreviations 
AC, adrenal crisis; AI, adrenal insufficiency; ACTH, adrenocorticotropic hormone; AGHD, adult growth 
hormone deficiency; ADH, antidiuretic hormone; AED, antiepileptic drug; BMI, body mass index; BMD, 
bone mineral density; CH, central hypothyroidism; CGS, Clinical Guidelines Subcommittee; CBG, 
corticosteroid-binding globulin; DDAVP, desmopressin; DI, diabetes insipidus; E2, estradiol; FSH, 
follicle-stimulating hormone; fT4, free thyroxine; fT3, free triiodothyronine; GH, growth hormone; GHD, 
growth hormone deficiency; GC, glucocorticoid; GnRH, gonadotropin-releasing hormone; GHRH, 
growth hormone-releasing hormone; HDL, high-density lipoprotein; HRT, hormonal replacement 
therapy; HC, hydrocortisone; HPA, hypothalamic-pituitary-adrenal; IGF-1, insulin-like growth factor-1; 
IM, intramuscular; IV intravenous; L-T4, levothyroxine; L-T3, levotriodothyronine; LDL, low-density 
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lipoprotein; LH, luteinizing hormone PTH, parathyroid hormone; PRL, prolactin; SHBG, sex hormone-
binding globulin; SIADH, syndrome of inappropriate antidiuretic hormone secretion; SMR, standard 
mortality ratio; T, testosterone; TBG, thyroid-binding globulin; TSH, thyrotropin; T4, thyroxine; T3, 
triiodothyronine; U.S., United States  
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Summary of Recommendations  
1. Diagnosis of Hypopituitarism  
Central Adrenal Insufficiency 
1.1 We suggest measuring serum cortisol levels at 8-9 a.m. as the first-line test for diagnosing central 
adrenal insufficiency (AI). (2|⊕OOO) 
 
1.2 We recommend against using a random cortisol level to diagnose AI. (1|⊕⊕OO) 
 
1.3 We suggest that a cortisol level <3 mcg/dl is indicative of AI, and a cortisol level >15 mcg/dl 
likely excludes an AI diagnosis. (2|⊕OOO)   
 
1.4 We suggest performing a corticotropin stimulation test when a.m. cortisol values are between 3-
15 mcg/dl to diagnose AI. Peak cortisol levels <18.1 mcg/dl (500 nmol/l) at 30 or 60 minutes indicate AI. 
(2|⊕⊕OO) 
 
1.5 We suggest that clinicians perform biochemical testing for the hypothalamic-pituitary-adrenal 
(HPA) axis at least 18-24 hours after the last hydrocortisone (HC) dose or longer for synthetic 
glucocorticoids (GCs). (2|⊕⊕OO) 
 
Central Hypothyroidism 
1.6 We recommend measuring serum free T4 (fT4) and TSH to evaluate central hypothyroidism 
(CH). An fT4 level below the laboratory reference range in conjunction with a low, normal, or mildly 
elevated TSH in the setting of pituitary disease usually confirms a CH diagnosis. (1|⊕⊕⊕⊕) 
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1.7 In patients with pituitary disease and low-normal fT4 levels suspected to have mild CH, we 
suggest starting levothyroxine (L-T4) if suggestive symptoms are present or following fT4 levels over 
time and starting treatment if the fT4 level decreases by 20% or more. (2|⊕OOO) 
 
1.8 We suggest against using dynamic TSH-secretion testing to diagnose CH. (2|⊕⊕⊕O)  
 
Growth Hormone Deficiency  
1.9 In patients with suspected GH deficiency (GHD), we recommend GH stimulation testing. Single 
GH measurements are not helpful. (1|⊕⊕⊕O) 
 
1.10 We recommend using appropriately controlled body mass index (BMI) cut-offs to assess peak 
GH values. (1|⊕⊕OO) 
 
1.11 We suggest against biochemical testing for GHD in patients with clear-cut features of GHD and 
three other documented pituitary hormone deficits. (2|⊕⊕⊕O) 
 
Central Hypogonadism in Males 
1.12 In males with suspected hypogonadism, we recommend measuring serum testosterone (T), FSH, 
and LH to diagnose central hypogonadism. (1|⊕⊕OO) 
 
1.13 We recommend that clinicians perform hormonal testing for central hypogonadism in males in 
the absence of acute/subacute illness and prior to 10 a.m. (following overnight fast) combined with serum 
prolactin (PRL). (1|⊕⊕OO)  
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Central Hypogonadism in Females  
1.14 In the presence of oligomenorrhea or amenorrhea, we recommend measuring serum estradiol 
(E2), FSH, and LH. Clinicians should exclude other causes of menstrual irregularities related to impaired 
ovulation (hyperprolactinemia, hyperandrogenism, and thyroid disease), particularly if no other pituitary 
hormone deficits are present. In cases of amenorrhea, clinicians should also exclude pregnancy. 
(1|⊕⊕OO) 
 
1.15 We suggest against dynamic testing with GnRH, which offers no useful diagnostic information. 
(2|⊕⊕OO) 
 
1.16 We recommend that in postmenopausal women, the absence of high serum FSH and LH are 
sufficient for a diagnosis of gonadotrope dysfunction (provided the patient is not on hormonal 
replacement therapy [HRT]). (1|⊕⊕⊕O) 
 
Central Diabetes Insipidus  
1.17 We recommend simultaneously measuring serum and urine osmolarity in patients with polyuria 
(more than 50 mL/Kg of body weight/24 hours, 3.5 L/day in a 70 kg person). In the presence of high 
serum osmolarity (>295 mosmol/L), urine osmolarity should reach approximately 600 mosmol/L (urine 
osmolality/plasma osmolality ratio should be ≥2); while urine dipstick should be negative for glucose. 
(1|⊕⊕⊕O) 
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2. Treatment 
Hormonal Replacement in Panhypopituitarism 
Glucocorticoid Replacement 
2.1 We recommend using HC, usually 15-20 mg total daily dose in single or divided doses. Patients 
using divided doses should take the highest dose in the morning at awakening and the second in the 
afternoon (2-dose regime) or the second and third at lunch and late afternoon, respectively (3-dose 
regime). (1|⊕⊕⊕O) 
 
2.2 We suggest using longer-acting GCs in selected cases (e.g., nonavailability, poor compliance, 
convenience). (2|⊕OOO) 
 
2.3 We recommend that clinicians instruct all patients to obtain an emergency card/bracelet/necklace 
regarding AI. (1|⊕⊕⊕O) 
 
2.4 We recommend against using fludrocortisone in patients with secondary AI. (1|⊕⊕⊕O) 
 
Adrenal Crisis 
2.5 We recommend that clinicians treat patients with suspected adrenal crisis (AC), due to secondary 
AI, with an immediate parenteral injection of 50-100 mg HC. (1|⊕⊕⊕O) 
 
Thyroid Hormone Replacement  
2.6 We recommend L-T4 in doses sufficient to achieve serum fT4 levels in the mid to upper half of 
the reference range. Appropriate L-T4 doses in CH average 1.6 mcg/kg/day, with dose adjustments based 
on clinical context, age, and fT4 levels. (1|⊕⊕⊕O) 
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2.7 We suggest against treating CH with levotriodothyronine (L-T3), thyroid extracts, or other 
formulations of thyroid hormones. (2|⊕⊕OO) 
 
2.8 We recommend against using serum TSH levels to adjust thyroid replacement dosing in patients 
with CH. (1|⊕⊕⊕O) 
 
Testosterone Replacement  
2.9 We suggest T replacement for adult males with central hypogonadism and no contraindications in 
order to prevent anemia related to T deficiency; reduce fat mass; and improve bone mineral density 
(BMD), libido, sexual function, energy levels, sense of well being, and muscle mass and strength. 
(2|⊕⊕OO) 
 
Estrogen Replacement in Premenopausal Women 
2.10 We recommend gonadal hormone treatment in premenopausal women with central 
hypogonadism, provided there are no contraindications. (1|⊕⊕⊕O) 
 
Growth Hormone Replacement Therapy 
2.11 We recommend offering GH replacement to those patients with proven GHD and no 
contraindications. We recommend a starting dose of 0.2-0.4 mg/day for patients younger than 60 years 
and 0.1-0.2 mg/day for patients older than 60 years. (1|⊕⊕⊕O) 
 
2.12 We recommend titrating GH doses and maintaining IGF-1 levels below the upper limit of 
normal and reducing the dose if side effects manifest. (1|⊕OOO) 
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2.13 We suggest against administering GH to elderly adults with age-adjusted low IGF-1 levels and 
no history of pituitary or hypothalamic disease. (2|⊕OOO)  
 
2.14 We recommend against using GH to enhance athletic performance, as this practice is illegal in 
the United States (U.S.), has poor scientific or ethical justification, and does not have substantiated 
efficacy. (Ungraded good practice statement) 
 
Diabetes Insipidus  
2.15 When administering desmopressin (DDAVP) in diabetes insipidus (DI), we suggest 
individualized therapeutic schedules. While clinicians should offer therapy to all patients, some patients 
with partial DI may not be bothered by polyuria and may prefer no treatment. To reduce the risk of 
hyponatremia, we recommend that clinicians educate all patients receiving DDAVP about the risk of 
overdosing. Periodically (at least weekly), patients should experience a phase of polyuria during which 
the effect of the medication has obviously worn off. (Ungraded good practice statement) 
 
2.16 In post-pituitary surgery DI, we suggest that clinicians should make at least one attempt to 
discontinue DDAVP during the weeks to months after surgery to determine if posterior pituitary function 
has recovered. (Ungraded good practice statement) 
 
2.17 In cases of adipsic DI, we suggest careful DDAVP and fluid intake titration that includes 
frequent weighing and serum sodium level monitoring. (Ungraded good practice statement) 
 
2.18 We suggest that all patients with DI wear an emergency bracelet or necklace to inform clinicians 
of the patient’s health problem if incapacitated. (Ungraded good practice statement) 
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Interactions Between Replacement Hormones  
 
Glucocorticoids and Growth Hormone  
2.19 We suggest testing HPA axis functionality before and after starting GH replacement in patients 
who are not receiving GC replacement and who have demonstrated apparently normal pituitary-adrenal 
function. (2|⊕OOO) 
 
Glucocorticoids and Thyroid Hormone 
2.20 We suggest evaluating patients with CH for AI prior to starting L-T4 therapy. If this is not 
feasible, clinicians should prescribe empiric GC therapy in patients with CH who are starting L-T4 
therapy until there is a definitive evaluation for AI. (2|⊕⊕OO) 
 
Glucocorticoids and Estrogen  
2.21 We suggest that when clinicians assess adrenal reserve or the adequacy of HC replacement they 
take into consideration that total serum cortisol level can be elevated due to the effects of estrogen on 
corticosteroid-binding globulin (CBG). (2|⊕⊕⊕O) 
 
Growth Hormone and Thyroid Hormones 
2.22 We recommend that clinicians monitor euthyroid patients with GHD who begin GH therapy for 
the risk of developing CH, and if fT4 levels decrease below the reference range, these patients should 
begin L-T4 therapy. CH patients with GHD who are already receiving L-T4 may require increased L-T4 
doses when they begin GH therapy to maintain fT4 levels within target ranges. (1|⊕⊕OO) 
 
2.23 We suggest clinicians treat CH before performing GH stimulation testing, because CH may 
impair the accurate diagnosis of GHD. (2|⊕⊕OO)  
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Estrogen and Thyroid Hormones 
2.24 In patients with CH requiring changes in estrogen therapy, we recommend monitoring fT4 levels 
and adjusting L-T4 doses to maintain fT4 levels within target ranges. (1|⊕⊕⊕O) 
 
Growth Hormone and Estrogen  
2.25 We suggest that women on oral estrogen replacement receive higher GH doses compared with 
eugonadal females or males. (2|⊕⊕⊕O) 
 
Glucocorticoids and Diabetes Insipidus 
2.26 Because AI may mask the presence of partial DI, we suggest monitoring for the development of 
DI after starting GC replacement. Conversely, patients with improved DI without an AI diagnosis should 
undergo AI testing. (2|⊕OOO) 
 
Risk of Hormonal Over-Replacement in Hypopituitarism  
Bone Disease 
2.27 Clinicians should individually assess GC replacement and avoid over-replacement to reduce the 
risk of osteoporosis. We suggest low-dose HC replacement, since this approach might be associated with 
increased bone formation and a positive bone remodeling balance. (2|⊕⊕OO) 
 
2.28 In men with hypopituitarism over-replaced with GC and at risk for fractures, we suggest 
vertebral fracture assessment (baseline plain spinal X-rays or dual-energy X-ray absorptiometry) to 
identify patients with unsuspected vertebral fractures. (2|⊕⊕OO) 
 
2.29 We suggest clinicians monitor L-T4 replacement, as recommended in previous sections, and 
avoid over-replacement to reduce the risk of fractures. (2|⊕⊕OO) 
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Cardiovascular Risks in Patients with Hypopituitarism on Replacement Therapy 
Glucocorticoid Over-Replacement  
2.30 In patients with central AI, we recommend using the lowest tolerable dose of HC replacement to 
potentially decrease the risks of metabolic and cardiovascular disease. (1|⊕⊕⊕O) 
 
Thyroid Replacement 
2.31 To avoid the possible long-term cardiovascular risks of insufficient or excess thyroid hormone 
treatment, clinicians should adjust L-T4 doses to avoid low or elevated fT4 levels in CH. (Ungraded  
good practice statement) 
 
3. Special Circumstances 
Cushing’s Disease  
3.1 We recommend GC replacement until full HPA axis recovery after surgically resecting ACTH-
secreting tumors. (1|⊕⊕⊕O) 
 
3.2 After curative surgery for Cushing’s disease, we recommend retesting thyroid and GH axes before 
starting replacement treatment. (1|⊕OOO) 
 
Prolactinomas 
3.3 We recommend reassessing the gonadotroph axis in patients with macroprolactinoma and central 
hypogonadism who have had successful dopamine agonist treatments. (1|⊕⊕⊕O)  
 
GH Replacement in Cured Acromegaly after Surgery and/or Radiation 
3.4 We suggest low-dose GH replacement in patients with cured acromegaly and documented GHD 
in the absence of known contraindications. (2|⊕OOO)  
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Perioperative Management of Hypopituitarism  
Pituitary Surgery 
3.5 We recommend using stress doses of steroids in AI before surgery and tapered doses after surgery 
before repeating testing. (1|⊕⊕⊕O) 
 
3.6 In patients with normal preoperative adrenal function, we suggest an individualized clinical 
approach for postoperative GC administration until the HPA axis can be evaluated. (2|⊕⊕OO) 
 
3.7 With preoperative CH, we recommend using L-T4 therapy before non-emergency surgery and 
throughout the perioperative period. (1|⊕⊕⊕O) 
 
3.8 With intact preoperative thyroid function, we recommend measuring fT4 levels 6-8 weeks post-
operatively to assess for CH. (1|⊕⊕OO) 
 
3.9 We suggest that initial therapy for DI utilizes short-acting subcutaneous aqueous antidiuretic 
hormone (ADH), allowing for safer use in the vast majority of cases in whom DI resolves spontaneously. 
(2|⊕⊕OO) 
 
3.10 We do not suggest pre-scheduled DDAVP dosages in the first week post-surgery because of the 
risk of hyponatremia after transient DI resolves and the risk of syndrome of inappropriate ADH secretion 
(SIADH) that may occur 7-10 days after surgery. (2|⊕OOO) 
 
3.11 We suggest oral or intranasal DDAVP after discharge, with clear instructions that patients 
should only use the medication if significant polyuria occurs. (2|⊕OOO) 
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3.12 We suggest retesting all pituitary axes starting at 6 weeks after pituitary surgery and then 
periodically to monitor the development or resolution of pituitary deficiencies. (2|⊕⊕OO) 
 
Non-Pituitary Surgery 
3.13 On the day of surgery, we recommend adjusting GC doses according to the severity of illness 
and magnitude of the stressor. (1|⊕⊕⊕O) 
 
3.14 In cases of minor to moderate surgical stress, we suggest 25-75 mg HC per 24 hours (usually for 
1-2 days). (2|⊕⊕OO) 
 
3.15 In cases of major surgical stress, we suggest a 100 mg HC per IV injection followed by a 
continuous IV infusion of 200 mg HC per 24 hours (alternatively 50 mg q6h IV or IM). (2|⊕⊕OO) 
 
Management of Hypopituitarism in Pregnancy 
Glucocorticoids  
3.16 We suggest using HC as the preferred GC in pregnancy and increasing the dose based on the 
individual clinical course; higher doses may be required, in particular during the third trimester. 
(Ungraded good practice statement) 
 
3.17 We suggest that pregnant patients with central AI be closely monitored for clinical symptoms 
and signs of glucocorticoid over- and under-replacement (e.g., normal weight gain, fatigue, postural 
hypotension or hypertension, hyperglycemia). (Ungraded good practice statement) 
 
3.18 We recommend against using dexamethasone in pregnancy, because it is not inactivated in the 
placenta. (1|⊕⊕OO) 
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3.19 We recommend HC stress dosing during the active phase of labor, similar to that used in major 
surgical stress. (1|⊕⊕OO) 
 
Thyroid  
3.20 We recommend that clinicians monitor fT4 or total T4 levels every 4-6 weeks for women with 
CH who become pregnant, and that these women may require increased L-T4 doses to maintain levels 
within target ranges for pregnancy. (1|⊕⊕OO)  
 
DDAVP 
3.21 In pregnant women with pre-existing DI, we suggest continuing DDAVP during pregnancy and 
adjusting doses if required. (2|⊕⊕OO) 
 
Growth Hormone  
3.22 We suggest discontinuing GH replacement during pregnancy, as there is no clear evidence yet 
for efficacy or safety, and the placenta produces GH. (2|⊕⊕OO)  
 
Management of Hypopituitarism in Pituitary Apoplexy 
3.23 We recommend testing for acute pituitary insufficiency in all patients with pituitary apoplexy. 
(1|⊕⊕⊕O) 
 
3.24 As acute AI is a major cause of mortality, we recommend GC therapy until a laboratory 
diagnosis is established and the patient maintains normal pituitary function. (1|⊕⊕OO)  
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3.25 We recommend that clinicians monitor pituitary axes in pituitary apoplexy patients treated with 
either surgical decompression or conservative management, as hypopituitarism may develop over time. 
(1|⊕⊕OO)  
 
Treatment of Hypopituitarism in Patients Receiving Antiepileptic Medications 
3.26 We suggest clinicians educate AI patients that are taking non-dexamethasone GCs and who start 
enzyme-inducing antiepileptic drugs (AEDs) about the early signs and symptoms of AI. (2|⊕⊕OO) 
 
3.27 In patients with AI on dexamethasone, we suggest increasing dexamethasone replacement doses 
if enzyme-induced AEDs are co-administered. (2|⊕OOO) 
 
3.28 In CH patients receiving L-T4, we recommend checking fT4 at least 6 weeks after starting an 
AED and increasing L-T4 doses if fT4 levels decrease below the target range. (1|⊕⊕OO) 
 
3.29 In women who have started estrogen replacement, we suggest evaluating AED levels and 
adjusting AED doses as required. (2|⊕⊕OO) 
 
3.30 We suggest monitoring DDAVP doses and making further adjustments as needed in patients 
who are started on AEDs. (2|⊕⊕OO) 
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Method of Development of Evidence-Based Clinical Practice Guidelines  
The Clinical Guidelines Subcommittee (CGS) of the Endocrine Society deemed hormonal 
replacement in hypopituitarism a priority area in need of practice guidelines and appointed a Task Force 
to formulate evidence-based recommendations. The Task Force followed the approach recommended by 
the Grading of Recommendations, Assessment, Development, and Evaluation group, an international 
group with expertise in the development and implementation of evidence-based guidelines (1). A detailed 
description of the grading scheme has been published elsewhere (2). The Task Force used the best 
available research evidence to develop the recommendations. The Task Force also used consistent 
language and graphical descriptions of both the strength of a recommendation and the quality of evidence. 
In terms of the strength of the recommendation, strong recommendations use the phrase “we recommend” 
and the number 1, and weak recommendations use the phrase “we suggest” and the number 2. Cross-filled 
circles indicate the quality of the evidence, such that ⊕OOO denotes very low quality evidence; ⊕⊕OO, 
low quality; ⊕⊕⊕O, moderate quality; and ⊕⊕⊕⊕, high quality. The Task Force has confidence that 
persons who receive care according to the strong recommendations will derive, on average, more good 
than harm. Weak recommendations require more careful consideration of the person’s circumstances, 
values, and preferences to determine the best course of action. Linked to each recommendation is a 
description of the evidence and the values that the Task Force considered in making the recommendation; 
in some instances there are remarks, a section in which the Task Force offers technical suggestions for 
testing conditions, dosing, and monitoring. These technical comments reflect the best available evidence 
applied to a typical person being treated. Often this evidence comes from the unsystematic observations 
of the Task Force and its values and preferences; therefore, one should consider these remarks as 
suggestions.  
 
 
Page 18 of 96 
 
JCEM 2nd SUBMISSION.  PLEASE DO NOT DISTRIBUTE. CONFIDENTIAL.  MAY 4, 2016 
 
In this guideline, the Task Force made several statements to emphasize the importance of shared 
decision-making, general preventive care measures, and basic principles of hormonal replacement in 
hypopituitarism. The Task Force labeled these as ungraded good practice statements. Direct evidence for 
these statements was either unavailable or not systematically appraised; therefore, the Task Force 
considers these statements out of the scope of this guideline. The intention of these statements is to draw 
attention to and remind providers of these principles; one should not consider these statements as graded 
recommendations (3). 
 
The Endocrine Society maintains a rigorous conflict-of-interest review process for developing clinical 
practice guidelines. All Task Force members must declare any potential conflicts of interest by 
completing a conflict-of-interest form. The CGS reviews all conflicts of interest before the Society’s 
Council approves the members to participate on the Task Force and periodically during the development 
of the guideline. All those participating in the guideline’s development must also disclose any conflicts of 
interest in the matter under study, and a majority of these participants must be without any conflicts of 
interest. The CGS and the Task Force have reviewed all disclosures for this guideline and resolved or 
managed all identified conflicts of interest.  
 
Conflicts of interest are defined as remuneration in any amount from commercial interest(s) in the 
form of grants; research support; consulting fees; salary; ownership interest (e.g., stocks, stock options 
[excluding diversified mutual funds]); honoraria or other payments for participation in speakers’ bureaus, 
advisory boards, or boards of directors; or other financial benefits. Completed forms are available through 
the Endocrine Society office. 
 
Funding for this guideline was derived solely from the Endocrine Society; the Task Force received no 
funding or remuneration from commercial or other entities. 
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Commissioned Systematic Reviews 
The guideline Task Force commissioned two systematic reviews to assist with summarizing the 
evidence base for this guideline.  
 
The first review addressed the question of whether adults with panhypopituitarism of any cause have 
increased all-cause mortality. The review identified 12 studies reporting on 26,017 patients. Studies were 
observational with incomplete adjustment for confounders. Meta-analysis suggested increased mortality 
in patients with panhypopituitarism (RR 1.55; 95% CI, 1.14-2.11). Factors associated with increased 
mortality were female gender, younger age at diagnosis, an underlying diagnosis of a craniopharyngioma 
or aggressive tumor, the presence of DI, and prior treatment with surgery or radiotherapy. The most 
common causes of death were malignancies, cardiovascular disease, and cerebrovascular disease.  
 
The second review attempted to answer the question of whether GH replacement is associated with a 
risk of pituitary tumor recurrence, secondary malignancy, or stroke. The review included seven studies 
reporting on 22,654 patients. Meta-analysis did not show an association between GH replacement and 
pituitary tumor recurrence (RR 0.87; 95% CI, 0.56-1.33) or the risk of secondary malignancies (RR 1.24; 
95% CI, 0.65-2.33). There were no data on the outcome of stroke.  
 
Each review addressed a question of association and both demonstrated that the evidence (overall) 
warrants low certainty in the provided estimates. 
 
Epidemiology, Morbidity, and Mortality of Hypopituitarism 
Hypopituitarism results from complete or partial deficiency in pituitary hormones and includes AI, 
hypothyroidism, hypogonadism, GHD, and (more rarely) DI. Not all disorders that affect anterior 
pituitary function may cause DI, and DI can occur without anterior pituitary dysfunction. Hypopituitarism 
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is the consequence of diseases that either reduce or destroy secretory function or interfere with the 
hypothalamic secretion of pituitary-releasing hormones.  
 
The prevalence (probably underestimated) is approximately 45 cases per 100,000 with an incidence 
of about four cases per 100,000 per year (4). Considering evidence from the commissioned systematic 
review and other evidence extracted mostly from contemporary studies on the management of 
hypopituitarism due to heterogeneous etiologies, it seems that mortality associated with hypopituitarism is 
indeed high (5-10). Recently published evidence indicates that pituitary hormonal deficits managed with 
the currently used replacement protocols (including non-supraphysiological doses of HC and appropriate 
thyroid and gonadal hormone replacement) might not adversely affect mortality (11). 
 
Hypopituitary patients exhibit increased incapacitation and sick days, lower health status, and higher 
cost of care (12,13). Those with GHD are less often working full time, and more often on sick 
leave/disability, often live alone, and often with parents (14). Despite receiving long-term GH 
replacement, the working capacity of hypopituitary patients remains lower than the general population 
(14). 
 
Given the complexity of hypopituitarism, patients are best managed in specialized centers, especially 
when they have enlarging pituitary tumors, desire pregnancy, have had pituitary apoplexy, are receiving 
multiple concomitant medications, and/or have a persistent decrease in quality of life (QOL). 
 
Central Adrenal Insufficiency 
Central AI represents inadequate cortisol secretion due to ACTH deficiency. It can be secondary, 
when pituitary disease impairs the release of ACTH, or tertiary from inadequate hypothalamic 
corticotropin-releasing hormone (15).  
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The prevalence of central AI (excluding exogenous steroids use) is 150-280 per million inhabitants 
(16); almost one-third of patients with pituitary failure may have AI (17-19). The reported prevalence 
after pituitary surgery varies (20-22), with up to 90% after craniopharyngioma surgery (23). Patients who 
have undergone cranial radiation for non-pituitary tumors have a high prevalence of hypopituitarism 
(24,25). The timing of onset of new pituitary deficiencies after radiation varies, but it may take a few 
years to develop in most cases (26). A high index of suspicion is required for diagnosing AI (27), as 
delaying treatment can result in AC and death. (16,28-30). Mild ACTH deficiency may manifest as 
clinically important AI with stress (31). 
 
Central Hypothyroidism  
CH is caused by insufficient TSH stimulation of a normal thyroid gland due to the inadequate 
secretion or action of TSH-releasing hormone and/or TSH (32,33). Acquired CH is usually associated 
with other pituitary hormone deficiencies.   
 
Approximately 50% of CH cases are caused by pituitary macroadenomas, while craniopharyngiomas 
are the most common extrasellar cause, especially in younger patients (33). The frequency of CH with 
nonfunctioning pituitary adenomas may reach 43% preoperatively and 57% post-operatively (34). CH 
occurs in up to 65% of patients irradiated for brain tumors, and up to half of patients irradiated for 
nasopharyngeal or paranasal sinus tumors. CH due to traumatic brain injuries or stroke may be increasing 
in prevalence, as more patients survive these events. 
 
Central Hypogonadism  
Central hypogonadism in males manifests with low serum T levels and features of T deficiency 
and/or impaired spermatogenesis. In premenopausal females, it manifests with low serum estrogens and 
impaired ovulation with oligomenorrhea or amenorrhea. 
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The prevalence can be as high as 95% in patients with sellar tumors and after surgery or radiotherapy; 
it’s also high for patients who have had cranial irradiation for non-sellar lesions (35-39). 
Hyperprolactinemia attributed to tumors or medications is also a common cause of hypogonadism (40). 
 
Untreated gonadotropin deficiency is an independent factor affecting mortality (HR 1.86 [99% CI 
1.15-2.45]), and sex steroid replacement has been associated with a significantly reduced standard 
mortality ratio (SMR) (1.42 [99% CI 0.97-2.07] vs. 2.97 [99% CI 2.13-4.13]) (men and women were not 
considered separately) (9). Androgen deprivation therapy in prostate cancer is associated with an 
increased incidence of myocardial infarctions and cardiovascular mortality (41-43) due to increased body 
weight, decreased lean body mass, increased serum low-density lipoprotein (LDL) and triglycerides, and 
reduced insulin sensitivity (43-46).  
 
Early menopause is associated with increased risk of cardiovascular and cerebrovascular disease (47-
50). Accordingly, bilateral oophorectomy without estrogen replacement before the age of 45 increases 
cardiovascular mortality (51). One study reported a SMR of 2.09 (95% CI 0.94-4.65) in females with 
untreated gonadotropin deficiency and an SMR of 0.94 (95% CI 0.35-2.49) in those with treated 
hypogonadism (52).  
 
Central (Neurogenic) Diabetes Insipidus  
Central (neurogenic) DI occurs when the secretion of ADH (also called vasopressin) by the posterior 
pituitary is insufficient to meet urine concentration requirements. The prevalence of medically treated DI 
is 7-10 patients per 100,000 inhabitants (53). DI can be congenital or acquired; it can be secondary to a 
variety of pathological processes including tumors (mostly craniopharyngioma and germinomas); head 
trauma; and inflammatory, autoimmune, granulomatous, infectious diseases involving the hypothalamus 
and/or posterior pituitary. Sometimes the cause of DI is unknown (“idiopathic DI”) and thought to be 
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autoimmune in nature. In some of these cases periodical follow-up imaging may unveil the cause, 
particularly in young patients (54). DI is very rarely encountered in non-operated pituitary adenomas (55).  
 
Adult Growth Hormone Deficiency 
Adult GHD (AGHD) may be present at childhood, or may occur during adulthood as an acquired 
condition. About 6,000 cases of AGHD are reported each year in the U.S. with an estimated 50,000 
diagnosed adults (56). In European reports, AGHD occurs at an annual incidence of 12-19 cases per 
million (57,58). The prevalence after traumatic brain injury is estimated at 12% (59). Whether or not adult 
GH replacement in patients with proven AGHD reduces mortality is not clear, as long-term controlled 
trials are lacking. However, GH replacement may reduce excess mortality from an SMR of 2.40 (95% CI 
1.46-3.34) to 1.99 (95% CI 1.21-2.76), especially in men (60). Untreated congenital GHD does not lead to 
shortened life expectancy (61).  
 
Prolactin Deficiency  
PRL deficiency is frequently seen in patients with hypothalamic-pituitary disease at presentation or 
after surgical and radiation treatment. Acquired PRL deficiency has been suggested as a marker for 
pituitary damage with a more severe degree of pituitary hypofunction (62). However, many cases of 
hypopituitarism are associated with hyperprolactinemia that occurs due to stalk interruption (63) and the 
absence of dopamine inhibition. 
 
Etiology, Clinical Manifestations 
We list the most frequent causes of acquired adult hypopituitarism in Table 1. 
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Table 1. Causes of Acquired Adult Hypopituitarism  
Neoplastic 
Pituitary adenoma 
Craniopharyngioma 
Meningioma 
Cysts (Rathke’s cleft, arachnoid, epidermoid, dermoid) 
Germinoma 
Glioma 
Astrocytoma 
Ganglioneuroma 
Paraganglioma 
Teratoma 
Chordoma 
Pituicytoma 
Ependymoma 
Pituitary carcinoma 
Metastases 
Infectious 
Bacterial 
Fungal 
Parasites 
Tuberculosis 
Syphilis 
 
Vascular 
Pituitary tumor apoplexy 
Sheehan’s syndrome 
Intrasellar carotid artery aneurysm 
Subarachnoid hemorrhage 
 
Traumatic 
Head injury  
 
Medications 
Opiates (primarily gonadotropin 
ACTH, GH) 
Glucocorticoids (ACTH only) 
Megestrol acetate (ACTH only) 
Somatostatin analogs (GH, 
ACTH,TSH) 
CTLA-4 blockers (ACTH, TSH, 
LH/FSH) 
 
    
 
Treatment of Sellar, Parasellar, and Hypothalamic 
Diseases 
Surgery 
Radiotherapy 
 
Infiltrative/Inflammatory Disease 
Autoimmune (lymphocytic hypophysitis, 
pituitary and POUF-1 antibodies) 
Hemochromatosis 
Granulomatous (granulomatosis with polyangiitis, 
sarcoidosis) 
Langerhans cell histiocytosis  
Giant cell granuloma 
Xanthomatous hypophysitis 
 
       
Empty Sella 
 
Idiopathic 
 
Abbreviations: CTLA-4, cytotoxic T-lymphocyte antigen 4; GCs, glucocorticoids [Adapted from Carmichael JD. 
Anterior pituitary failure In: Melmed S, ed. The Pituitary 3rd ed: Elsevier; 2011:343-381, with permission, © Elsevier 
(66).] 
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The most common cause of central AI is exogenous GCs that suppress ACTH; however, this review 
focuses on endogenous hypopituitarism.  
 
The usual sequential pattern for hormonal deficiencies is the loss of GH initially, followed by 
gonadotropins, TSH, and ACTH, but there are several exceptions to this order (e.g., hypophysitis). 
Therefore, it can be challenging to ascribe specific features to a single hormone deficiency. We list 
relevant clinical features for each pituitary hormone deficiency in Table 2. 
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Table 2. Clinical Manifestations of Hypopituitarism 
Symptom/Sign Pituitary Trophic Hormone  Deficiency 
General  
   Fatigue, weakness ACTH, TSH, LH/FSH, GH 
   Weight gain TSH 
   Weight loss ACTH 
   Decreased exercise capacity ACTH, TSH, LH/FSH, GH 
   Impaired sleep quality TSH, LH/FSH, GH 
   Depression TSH, GH, LH/FSH 
   Cognitive decline ACTH, TSH, ?GH 
   Cold intolerance TSH 
Skin  
   Pallor ACTH, LH/FSH 
   Dry skin ACTH, TSH 
   Thinning hair, loss of body hair ACTH, TSH, LH/FSH 
Cardiovascular/Metabolic  
   Hypertension TSH, GH 
   Hypotension, particularly orthostatic ACTH 
   Bradycardia TSH 
   Decreased lean body mass, increased fat  
   mass 
GH 
   Hyperlipidemia TSH, GH 
   Insulin resistance, impaired glucose 
   tolerance 
TSH, GH   
   Hypoglycemia ACTH 
   Impaired cardiac function ACTH, TSH, GH 
   Premature atherosclerosis TSH, GH 
Pulmonary  
   Shortness of breath, dyspnea on exertion ACTH, TSH 
Gastrointestinal  
   Anorexia ACTH 
   Nausea/vomiting ACTH 
   Diarrhea/loose stools ACTH 
   Constipation TSH 
Musculoskeletal  
   Muscle weakness ACTH, TSH, LH/FSH, GH 
   Osteoporosis, fractures ACTH, TSH, LH/FSH, GH 
Renal  
   Increased thirst ADH 
   Polyuria, nocturia ADH 
Reproductive  
   Oligo/amenorrhea ACTH, TSH, LH/FSH 
   Erectile dysfunction LH/FSH 
   Low libido LH/FSH 
   Hot flashes LH/FSH 
   Infertility LH/FSH 
   Vaginal dryness LH/FSH 
Abbreviations: ADH, antidiuretic hormone [Derived from Jameson LJ. Harrison’s Endocrinology, Ch 2, Melmed, 
Jameson (Reference Pending).] 
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1. Diagnosis of Hypopituitarism 
 
Establishing the diagnosis and monitoring therapy of hypopituitarism requires an understanding of 
hormonal assay characteristics and limitations (Appendix A).  
 
In several instances where data were lacking on the central deficiency state, we extrapolated it from 
studies on primary gland failure. However this evidence may or may not be directly applicable to central 
pituitary deficiencies.   
 
Central Adrenal Insufficiency 
Clinicians can assess central AI using insulin tolerance and low-dose and standard-dose ACTH 
stimulation tests (Table 3). Limitations include interpreting test cut-off values and thresholds required for 
GC replacement (17,25,64-71). Although assays have evolved, cortisol levels <18.1 mcg/dl (500 nmol/l) 
post-stimulation are indicative of AI (Table 3). The Endocrine Society clinical practice guidelines for 
primary AI include details on additional tests (72). 
 
1.1 We suggest measuring serum cortisol levels at 8-9 a.m. as the first-line test for diagnosing central 
AI. (2|⊕OOO) 
 
1.2 We recommend against using a random cortisol level to diagnose AI. (1|⊕⊕OO) 
 
1.3 We suggest that a cortisol level <3 mcg/dl is indicative of AI, and a cortisol level >15 mcg/dl 
likely excludes an AI diagnosis. (2|⊕OOO)   
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1.4 We suggest performing a corticotropin stimulation test when a.m. cortisol values are between 3-
15 mcg/dl to diagnose AI. Peak cortisol levels <18.1 mcg/dl (500 nmol/l) at 30 or 60 minutes indicate AI. 
(2|⊕⊕OO) 
 
1.5 We suggest that clinicians perform biochemical testing for the HPA axis at least 18-24 hours after 
the last HC dose or longer for synthetic GCs. (2|⊕⊕OO) 
 
Evidence 
The Endocrine Society has published a guideline on the diagnosis of primary AI (72). While high 
ACTH values are diagnostic of primary AI, the finding of a random low normal ACTH level may not be 
helpful in diagnosing central AI (73).  
 
As GCs suppress the HPA axis, and there are interferences in cortisol measurements, clinicians 
should perform biochemical testing at least 18-24 hours after the last HC dose or longer for synthetic GCs 
(74). Clinicians should also consider the duration of GC treatment and the influence of oral estrogen on 
total serum cortisol levels, which can increase CBG.   
 
Central Hypothyroidism 
1.6 We recommend measuring serum fT4 and TSH to evaluate CH. An fT4 level below the laboratory 
reference range in conjunction with a low, normal, or mildly elevated TSH in the setting of pituitary 
disease usually confirms a CH diagnosis. (1|⊕⊕⊕⊕) 
 
1.7 In patients with pituitary disease and low-normal fT4 levels suspected to have mild CH, we 
suggest starting L-T4 if suggestive symptoms are present or following fT4 levels over time and starting 
treatment if the fT4 level decreases by 20% or more. (2|⊕OOO) 
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1.8 We suggest against using dynamic TSH-secretion testing to diagnose CH. (2|⊕⊕⊕O)  
 
Evidence 
TSH levels in CH may be low, normal, or slightly elevated, reflecting decreased 24-hour secretion 
and altered bioactivity with relatively preserved immunoactivity (75-77). In contrast to primary 
hypothyroidism, TSH and fT4 levels do not correlate (33). Accordingly, clinicians cannot use TSH levels 
alone to diagnose or monitor CH. 
 
The combination of a low fT4 and a non-markedly-elevated TSH in patients with known pituitary 
disease is diagnostic of CH, unless a patient is severely ill and could have nonthyroidal illness-induced 
changes in thyroid hormone levels. However, this approach may miss a significant number of patients 
with mild CH, as some pituitary patients with low-normal fT4 levels may have mild CH. Since patients 
with primary hypothyroidism usually require high-normal or slightly elevated fT4 levels to normalize 
TSH levels (78), low-normal fT4 levels in hypopituitary patients may suggest the presence of CH. 
Although, it is difficult to confirm this, since by definition many healthy subjects have fT4 levels in the 
lower part of the laboratory reference range, and there are no validated measures of thyroid function in 
hypopituitary patients. Studies have suggested that 10-18% of high-risk pituitary patients have 
unrecognized CH with low-normal fT4 levels (77,79). These patients often have a blunted or absent 
nocturnal surge in TSH levels, but this is impractical for diagnostic use (33). Suggested approaches for 
patients with low-normal fT4 levels include starting L-T4 if suggestive symptoms are present, or 
following fT4 levels over time and starting treatment if the fT4 level decreases by 20% (77). However, 
these recommendations have not been systematically investigated.  
 
Serum T3 or free T3 (fT3) levels are generally not helpful in diagnosing CH; most patients with CH 
have low fT3 levels, but there is considerable overlap between CH and non-CH patients with pituitary 
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disease (75,77). Peripheral indices of thyroid hormone action lack sufficient sensitivity and specificity for 
diagnosing or monitoring (33,80-82). 
 
Past studies have attempted to categorize CH based on TSH responsiveness to exogenous TSH-
releasing hormone administration (83), but this has not proven to be useful in clinical practice.  
 
Growth Hormone Deficiency  
1.9 In patients with suspected GHD, we recommend GH stimulation testing. Single GH 
measurements are not helpful. (1|⊕⊕⊕O) 
 
1.10 We recommend using appropriately controlled BMI cut-offs to assess peak GH values. 
(1|⊕⊕OO) 
 
1.11 We suggest against biochemical testing for GHD in patients with clear-cut features of GHD and 
three other documented pituitary hormone deficits. (2|⊕⊕⊕O) 
 
Evidence 
GHD is measured via insulin tolerance, glucagon, and (if available) GHRH + arginine tests. The 
Endocrine Society guidelines extensively reviewed these and we listed them in Table 3 (84). 
 
Diagnosis in adults with a prior diagnosis of childhood-onset GHD (congenital or acquired) is 
relatively straightforward, as these patients had short stature. However, as clinical features of acquired 
AGHD are often subtle, not necessarily specific to an underlying pituitary disorder, and commonly 
encountered in the general population, these patients should all be re-tested as adults. Normal GH 
secretion is characterized by a heterogeneous pulsatile pattern; therefore, measuring basal circulating GH 
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levels does not provide useful diagnostic information. While interpreting GH values, one should also 
consider multiple factors, including nutritional and hormonal status, exercise, body weight, and age, all of 
which may influence pituitary GH secretion (85,86).  
 
Unlike GH, IGF-1 levels are relatively reproducible and stable, with a circulating half-life of 24-30 
hours. Age-adjusted values measured in an accredited laboratory provide valuable information of net GH 
bioactivity. Nevertheless, about 20% of adults with GHD may have normal IGF-1 levels, particularly 
males (85). 
 
Remarks 
As most GH reserve tests are associated with high false positive rates, patients should have a rigorous 
biochemical evaluation only when there is a high probability for GHD. One or more of the following 
prescreening criteria should be fulfilled: 
 
• Young adults previously requiring GH therapy for short stature during childhood (isolated 
GHD with normal pituitary imaging) should all be retested as adults before continuing adult 
GH replacement. Many of these patients prove to be GH-sufficient on subsequent retesting.  
 
• Patients should exhibit evidence for pituitary damage including a history of pituitary surgery 
or irradiation for a demonstrated intrasellar lesion, pituitary hypoplasia, hypothalamic mass or 
infiltration, prior head trauma, contact-sports injury, or stroke. 
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Table 3. Dynamic Tests for Diagnosing Suspected Hypopituitarism 
Hormone Test Procedure Interpretation/ Expected 
Normal Response 
GH 
 
 
Insulin tolerance  
 
 
 
 
 
GHRH*+arginine  
 
 
 
 
 
 
 
 
Glucagon  
Administer insulin, 0.05-0.15 
U/kg IV. 
Sample blood at -30, 0, 30, 60, 
120 minutes for GH and glucose. 
 
 
Administer GHRH, 1 mcg/Kg 
(max 100 mcg) IV followed by an 
arginine infusion 0.5 g/Kg (max 
35 g) over 30 minutes. 
Sample blood at 0, 30, 45, 60, 
75, 90, 105, and 120 minutes for 
GH. 
 
 
Administer glucagon, 1 mg (1.5 
mg if weight >90 Kg) IM. 
Sample blood at 0, 30, 60, 90, 
120, 150, 180, 210, and 240 
minutes for GH and glucose. 
Glucose should drop <40 
mg/dl, (2.2 mmol/L). 
GH should be >3-5 mcg/L. 
Cut-offs for GH response 
are BMI-related. 
 
Can give false normal GH 
response if GHD is due to 
hypothalamic damage (e.g., 
following radiation). 
Cut-offs for GH response 
should be correlated to BMI. 
(Obesity may blunt GH 
response to stimulation.) 
 
ACTH  
 
 
 
 
 
 
Insulin tolerance  
 
 
 
 
 
 
Corticotropin 
standard dose  
(250 mcg) 
 
 
Corticotropin low 
dose (1 mcg) 
 
 
Administer insulin, 0.05-0.15 
U/kg IV. 
Sample blood at -30, 0, 30, 60, 
and 120 minutes for cortisol and 
glucose. 
 
 
Administer ACTH 1-24 
(cosyntropin), 250 mcg IM or IV. 
Sample blood at 0, 30, and 60 
minutes for cortisol. 
 
Administer ACTH 1-24 
(cosyntropin), 1 mcg IV. 
Sample blood at 0 and 30 
minutes for cortisol. 
 
Glucose should drop <40 
mg/dl (2.2 mmol/L). 
Peak cortisol should be 
>500-550 nmol/l (>18.1-20 
mcg/dL) depending on 
assay. 
 
Cortisol should be at 30 or 
60 minutes >500-550 nmol/l 
(>18.1-20 mcg/dL) 
depending on assay. 
 
Cortisol should be at 30 
minutes >500 nmol/l (18.1 
mcg/dl) depending on 
assay. 
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Hormone Test Procedure Interpretation/ Expected 
Normal Response 
ADH Water 
deprivation  
test  
Initiate fluid deprivation for 8 
hours (starting from 8 a.m.).  
Weigh patient at beginning of 
testing, then measure weight and 
urine volume hourly during the 
test.   
Measure plasma and urine 
osmolality every 2-3 hours. 
At 4 p.m. administer DDAVP 2 
mcg IM and allow patient to drink 
freely. 
Notes: If plasma osmolality >305 
mOsm/Kg or if 3% loss of body 
weight with plasma osmolality 
>305 mOsm/Kg, proceed to 
DDAVP administration earlier. If 
urine output has not decreased 
and/or urine osmolality/plasma 
osmolality ratio <2, but the 
plasma osmolality has not 
concentrated to >295 mOsm/kg, 
continue water deprivation for a 
further hour and measure plasma 
and urine osmolality. Offer 
DDAVP after this.  
Continue measuring urine 
osmolality hourly for the next 4 
hours (after DDVAP 
administration) and measure 
hourly urine volumes. 
Stop test if >3% weight loss 
occurs. 
Plasma osmolality >295 
mOsm/l with inappropriately 
hypotonic urine (urine 
osmolality/plasma 
osmolality ratio <2) during 
the fluid deprivation 
confirms DI (test is 
discontinued).  
After administering DDVAP, 
urine concentrates >800 
mOsm/Kg with central DI 
and <300 mOsm/Kg with 
nephrogenic DI. 
With partial DI or primary 
polydipsia, urine 
concentrates partially during 
the water deprivation test 
(300-800 mOsm/Kg), and 
further investigation is 
required including a 
prolonged water deprivation 
test or DDVAP therapeutic 
trial.  
*Presently unavailable in the United States. 
Abbreviations: DDVAP, desmopressin; DI, diabetes insipidus; BMI, body mass index; GHD, growth hormone 
deficiency; ADH, antidiuretic hormone [Derived from Bornstein SR, Allolio B, Arlt W, Barthel A, Don-Wauchope A, 
Hammer GD, Husebye ES, Merke DP, Murad MH, Stratakis CA, Torpy DJ. Diagnosis and Treatment of Primary 
Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2016; 101:364-389 
(72) 
Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth 
hormone deficiency: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 2011; 96:1587-1609 
(84) 
Jameson LJ. Harrison’s Endocrinology, Ch 2, Melmed, Jameson (Reference Pending) 
Webb R, Singer M. Oxford handbook of Critical Care. Oxford; New York: Oxford University Press, 2005 (Reference 
Pending)] 
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Central Hypogonadism in Males 
 
1.12 In males with suspected hypogonadism, we recommend measuring serum T, FSH, and LH to 
diagnose central hypogonadism. (1|⊕⊕OO) 
 
1.13 We recommend that clinicians perform hormonal testing for central hypogonadism in males in 
the absence of acute/subacute illness and prior to 10 a.m. (following overnight fast) combined with serum 
PRL. (1|⊕⊕OO)  
 
Evidence 
Central hypogonadism in males manifests with low serum T levels and features of T deficiency 
and/or impaired spermatogenesis. 
 
T levels (total, free, and bioavailable) demonstrate a circadian rhythm with maximum serum values 
between 5:30 and 8 a.m. and trough levels approximately 12 hours later (87-89). Acute/subacute illness 
alters T levels acting at various levels of the hypothalamo-pituitary-gonadal axis (90,91). Systemic 
diseases, eating disorders, extensive exercise, and a number of medications or recreational drugs (e.g., 
GCs, opiates, ketoconazole, barbiturates, cocaine) affect T levels (92,93). Hyperprolactinemia can cause 
hypogonadotropic hypogonadism, and clinicians need to take into account the possibility of a 
prolactinoma, as dopamine agonist treatment can reverse the hypogonadism. Two measurements 
performed with the same assay are preferred for borderline low T values (94,95). 
 
Remarks 
T levels demonstrate an age-related decline (96,97). The Massachusetts Male Aging Study has shown 
that in healthy men serum T reaches the highest levels at around the age of 30 years with a gradual 
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decline thereafter at a rate of 1-2% annually (96). The level of serum T below which symptoms of 
hypogonadism occur has not been clearly established.  
 
About 2% of circulating T is free (unbound), 44% is bound to sex hormone-binding globulin 
(SHBG), and 54% is bound to albumin and other proteins (98). Total T levels at the low end of the 
reference range are associated with conditions or medications affecting SHBG and albumin (e.g., 
hypothyroidism/hyperthyroidism, obesity, diabetes mellitus, nephrotic syndrome, liver disease, HIV 
infection, GCs, or anticonvulsants). When assessing fertility is required, clinicians should perform semen 
analysis before starting T replacement. Notably, one study reported cases of males with acquired 
hypogonadotropic hypogonadism remaining fertile after T treatment (99). 
 
Central Hypogonadism in Females  
1.14 In the presence of oligomenorrhea or amenorrhea, we recommend measuring serum E2, FSH, 
and LH. Clinicians should exclude other causes of menstrual irregularities related to impaired ovulation 
(hyperprolactinaemia, hyperandrogenism, and thyroid disease), particularly if no other pituitary hormone 
deficits are present. In cases of amenorrhea, clinicians should also exclude pregnancy. (1|⊕⊕OO) 
 
1.15 We suggest against dynamic testing with GnRH, which offers no useful diagnostic information. 
(2|⊕⊕OO) 
 
1.16 We recommend that in postmenopausal women, the absence of high serum FSH and LH are 
sufficient for a diagnosis of gonadotrope dysfunction (provided the patient is not on HRT). (1|⊕⊕⊕O) 
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Evidence 
The diagnosis of central hypogonadism is females requires the exclusion of other conditions causing 
impaired ovulation and menstrual irregularities, including hyperprolactinaemia, hyperandrogenism, and 
thyroid dysfunction (40). The value of GnRH testing provides no extra diagnostic information over that 
derived from baseline gonadotropin values measured by currently available ultrasensitive assays (100). 
Furthermore, one study proposed that in patients with hypogonadotropic hypogonadism the GnRH 
responses are variable and depend on the severity of gonadotropin deficiency, which is often reflected by 
the clinical phenotype (100). 
 
HRT invariably causes a reduction in circulating FSH and LH levels (101). Clinicians could observe 
reductions of up to 60% for FSH and 50% for LH. 
 
Central Diabetes Insipidus  
1.17 We recommend simultaneously measuring serum and urine osmolarity in patients with polyuria 
(more than 50 mL/Kg of body weight/24 hours, 3.5 L/day in a 70 kg person). In the presence of high 
serum osmolarity (>295 mosmol/L), urine osmolarity should reach approximately 600 mosmol/L (urine 
osmolality/plasma osmolality ratio should be ≥2); while urine dipstick should be negative for glucose. 
(1|⊕⊕⊕O) 
 
Evidence 
The presence of DI may be obvious with severe forms in the appropriate clinical scenario (e.g., after 
surgery for hypothalamic or pituitary lesion). More subtle cases require a water deprivation test to 
document partial inability to concentrate urine. The diagnosis may be particularly challenging when DI is 
partial and magnetic resonance imaging (MRI) imaging does not show an obvious pathology. However, 
in most cases of isolated DI, MRI imaging of the sellar area shows a progressive loss of the posterior 
pituitary bright spot (102). 
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Hormone Assays  
Accurate and reliable hormonal measurements are central to diagnosing and monitoring therapeutic 
interventions. Technical considerations include assay characteristics (such as sensitivity and reliability at 
low levels), sample stability, and interference from replacement hormonal therapies and their analogues 
(e.g., prednisolone and HC in cortisol assays). 
 
We reviewed the performance characteristics (sensitivity, specificity, variability [precision], and 
sample limitations) of widely used assays for GH, IGF-1, PRL, FSH, LH, TSH, fT4, T, E2, cortisol, and 
ACTH (Appendix A). All assays exhibited adequate sensitivity and acceptable intra-assay variability at 
<20% (Appendix A). However, some analytes, such as E2, T, GH, fT4, and to a lower extent 
gonadotropins, had large inter-assay variability; therefore, clinicians should consider differences among 
assays and use the same assay for serial and longitudinal measurements (Appendix A) (103).  
 
Clinicians need to follow precautions for sample integrity, and should consider sample storage and 
handling (freeze-thaw) when reviewing questionable results. 
 
Clinicians are increasingly using newer liquid chromatography-mass spectrometric-based assays with 
suggested improved sensitivity and reduced interference. This is particularly true for steroids, namely E2, 
T (104,105), and thyroid and peptide hormones (78,106). 
 
2. Treatment 
Hormonal Replacement in Panhypopituitarism 
As a guiding principle, the Task Force suggests hormonal replacement as close to the physiological 
pattern as possible.  
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Glucocorticoid Replacement 
2.1 We recommend using HC, usually 15-20 mg total daily dose in single or divided doses. Patients 
using divided doses should take the highest dose in the morning at awakening and the second in the 
afternoon (2-dose regime) or the second and third at lunch and late afternoon, respectively (3-dose 
regime). (1|⊕⊕⊕O) 
 
2.2 We suggest using longer-acting GCs in selected cases (e.g., nonavailability, poor compliance, 
convenience). (2|⊕OOO) 
 
2.3 We recommend that clinicians instruct all patients to obtain an emergency card/bracelet/necklace 
regarding AI. (1|⊕⊕⊕O) 
 
2.4 We recommend against using fludrocortisone in patients with secondary AI. (1|⊕⊕⊕O) 
 
Evidence 
Total daily dose. Daily physiologic cortisol production in healthy individuals is about 5-10 mg per 
square meter of body surface area (107), corresponding to a replacement dose of approximately 15-20 
mg/day. Many believe that a dose in this range may avoid under- or over-treatment. As no reliable marker 
to determine exact GC needs is available, initial dose requirements are largely estimated. Further dose 
adjustments depend on clinical status, patient preference, and co-morbidities.  
 
Researchers have used a cortisol day curve (108), but it has little value for routine clinical use (28). 
Prednisolone cross-reacts in many cortisol assays, while dexamethasone exhibits limited cross-reactivity. 
Urine-free cortisol measurements have wide inter- and intra-variability, and thus are rarely useful 
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(109,110). For patients with suspected malabsorption or increased steroid metabolic clearance, serial 
measurements of blood cortisol might be useful (28).  
 
Stress doses of GC replacement for intercurrent illnesses and minor stress are similar to those used in 
primary AI (72). A recent guideline reviewed the prevention of AC and the importance of patient 
education (72).  
 
Circadian rhythm-multiple daily dosing. Cortisol secretion exhibits a distinct circadian rhythm; low 
at the time of sleep onset, rising early morning, peaking just after the time of waking, then falling during 
the day (28,107). No currently available GC treatment regimen is capable of accurately simulating the 
normal cortisol circadian rhythm. Clinicians currently prescribe several regimens, either weight-based 
(111) or multiple fixed doses 2-3 times per day (28,110,112). Weight-adjusted, 3-times-daily dosing using 
HC reduces GC overexposure and represents the most refined regime available, although it does not 
replicate the normal cortisol rhythm (113). Clinicians also frequently prescribe single daily HC doses in 
patients with central AI (114,115). 
 
Type of glucocorticoid replacement. Published surveys of current practice for GC replacement 
therapy include mostly patients with primary AI, however some studies also include patients with central 
AI (116). HC is the most common GC used for replacement, followed by prednisone, cortisone, and 
dexamethasone. 11 β-hydroxisteroid dehydrogenase-1 converts cortisone acetate to biologically active 
cortisol, which might reduce circulating cortisol fluctuations (110). One can compare GCs of different 
potencies by calculating the HC equivalence based on anti-inflammatory effects (Table 4) (28,110,117-
119). However, this method might sometimes overestimate the calculation of a replacement dose. 
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Table 4. Dose Equivalence for Glucocorticoids  
Equivalent Dose Glucocorticoids 
20 mg HC 
5 mg Prednisone 
0.75 mg Dexamethasone 
4 mg Methylprednisolone 
5 mg Prednisolone 
25 mg Cortisone 
Abbreviations: HC, hydrocortisone [Derived fromJameson LJ. Harrison’s Endocrinology, Ch 2, Melmed, Jameson 
(Reference Pending) 
Adapted from Webb R, Singer M. Oxford handbook of Critical Care. Oxford; New York: Oxford University Press, 
2005, with permission, © Oxford University Press (Reference Pending).] 
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A high proportion of patients on “conventional” corticosteroid replacement therapy for AI are over 
treated or on inappropriate replacement regimens (120). Few studies have compared different 
replacements regimens for central AI. However, a lower doses of HC seems to correlate with improved 
QOL, health status, and mood. In a randomized, double blind, crossover design (121), patients received 
varying multiple doses of HC versus prednisone for 4 weeks at each dose. The HC 10 mg a.m./5 mg p.m. 
regimen showed improved physical QOL, but overall QOL did not differ between regimens and remained 
lower than in healthy controls. In a cross-sectional study (27), HC doses above 30 mg/day were associated 
with adverse health status by validated self-assessment questionnaires. Three-times-daily intake of HC 
was not superior to 2-times-daily intake. In 2,737 adult hypopituitary patients (122), those receiving the 
equivalent of ≤10  mg HC had the best QOL, and those receiving ≥25  mg HC had the poorest QOL. These 
effects could be due to supraphysiological GC exposure, but it is possible that clinicians may have 
increased the GC doses to address unexplained QOL deficits. In a randomized, double blind, crossover 
design (121), patients received varying multiple doses of HC versus prednisone for 4 weeks at each dose. 
The HC 10 mg a.m./5 mg p.m. regimen showed improved physical QOL, but overall QOL did not differ 
between regimens and remained lower than in healthy controls.  
 
New glucocorticoid preparations (not United States Food and Drug Administration approved). 
Modified release HC is commercially approved in Europe as a once-a-day tablet with combined 
immediate and extended release characteristics capable of achieving a more physiological plasma cortisol 
profile. However, the physiological rise in cortisol early morning is not well mimicked (123-125). The 
primary AI guideline reviewed the new GC preparations (72). 
 
Androgen Replacement in Women 
Recent Endocrine Society guidelines have reviewed the risks and benefits of androgen replacement in 
women (126). The authors recommended against the routine use of dehydroepiandrosterone due to limited 
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data concerning its effectiveness and safety in women with AI. The same authors also recommended 
against the routine prescription of T in women with hypopituitarism (126). 
 
Adrenal Crisis 
2.5 We recommend that clinicians treat patients with suspected AC, due to secondary AI, with an 
immediate parenteral injection of 50-100 mg HC. (1|⊕⊕⊕O) 
 
Evidence 
AC may be the initial presenting feature of pituitary failure. Despite intact mineralocorticoid function, 
patients with secondary AI have a similar (if not higher) risk of AC (19,29-31,110,112). Excess 
cardiovascular mortality might be specifically related to AC (30). Crisis incidence is not influenced by 
educational status, BMI, GC dose, dehydroepiandrosterone treatment, age at diagnosis, hypogonadism, 
hypothyroidism, or GHD. Interestingly, the female sex and presence of DI in AC correlated with hospital 
admission in one study (29). 
 
The need for immediate GC replacement and fluid resuscitation is the same in central AI as it is in 
primary AI (72). Patient education is considered the key to preventing AC. All patients should receive 
detailed information on their disease and GC adjustment requirements for stressful situations. Patients 
should carry an emergency card, bracelet or necklace, and GCs for emergency administration. These 
include intramuscular or subcutaneous HC preparations designed for self-injection (72). 
 
Thyroid Hormone Replacement  
2.6 We recommend L-T4 in doses sufficient to achieve serum fT4 levels in the mid to upper half of 
the reference range. Appropriate L-T4 doses in CH average 1.6 mcg/kg/day, with dose adjustments based 
on clinical context, age, and fT4 levels. (1|⊕⊕⊕O) 
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2.7 We suggest against treating CH with L-T3, thyroid extracts, or other formulations of thyroid 
hormones. (2|⊕⊕OO) 
 
Evidence 
The standard therapy for CH is L-T4 (~1.6 mcg/kg/day). In a randomized, double blind, crossover 
study, 32 hypopituitary CH patients received L-T4 doses previously adjusted by endocrinologists using 
best clinical judgment (80). Increasing the L-T4 dose from a mean of 1.0 to a mean of 1.6 mcg/kg/day led 
to mild weight loss; improvements in hypothyroid symptom scores; and decreased BMI, total and LDL 
cholesterol levels, and serum CK levels. When clinicians substituted L-T3 for some of the L-T4, working 
memory was slightly better but at the expense of T3 levels above the reference range. Based on these 
results, the authors recommended an L-T4 dose of 1.6 mcg/kg/day in CH, with a target fT4 level close to 
the upper limit of the reference range. Nonrandomized and observational studies also report similar 
findings, with improved fatigue, weight or BMI, waist circumference, and cholesterol levels correlating 
with higher L-T4 doses and fT4 levels (75,77,127-129). One cross-sectional study of CH patients reported 
that mean L-T4 doses of 1.9 mcg/kg led to fT4 levels in the upper half of the normal range (130). 
However, a recent publication reported that increased risk of vertebral fracture in hypopituitary patients 
receiving higher daily doses of L-T4 correlated with higher fT4 levels (131). Therefore, clinicians should 
adjust L-T4 doses for age, estrogen status (including pregnancy, see below), co-morbidities, and clinical 
context, including potential risks of overtreatment (33). Some investigators recommend following fT3 
levels or peripheral indicators of thyroid function during L-T4 therapy, since elevated fT3 levels can 
indicate overtreatment, although studies have not validated this (33,77).  
  
Few studies have examined the use of L-T3 or other formulations of thyroid hormone for CH (80); 
there are no high-quality studies that document the superiority of these treatments over L-T4 in primary 
hypothyroidism, and there are potential safety concerns (reviewed in 76). Alternate preparations of 
thyroid hormones or nutraceuticals are not recommended for treating CH. 
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2.8 We recommend against using serum TSH levels to adjust thyroid replacement dosing in patients 
with CH. (1|⊕⊕⊕O) 
 
Evidence 
Many patients with CH have undetectable TSH levels on presentation, and almost all CH patients 
adequately treated with L-T4 to maintain serum fT4 levels in the mid- to high-normal range will have 
undetectable TSH levels (75,80,127,129). Therefore, clinicians should not interpret undetectable TSH 
levels as a sign of overtreatment in CH, even in patients with initial measurable TSH levels. 
 
Remarks 
In most clinical situations, patients receiving L-T4 undergo blood sampling in the morning prior to 
taking their daily L-T4 dose, or at random times during the day. It is not clear whether the timing of blood 
sampling in relation to L-T4 dose ingestion affects decisions regarding L-T4 dose adjustment in CH. A 
randomized controlled study of CH (80) measured fT4 levels 2 hours after dose ingestion and reported 
slightly elevated mean fT4 levels with adequate doses. Therefore, we recommend checking fT4 before the 
L-T4 dose. 
 
Testosterone Replacement  
2.9 We suggest T replacement for adult males with central hypogonadism and no contraindications in 
order to prevent anemia related to T deficiency; reduce fat mass; and improve BMD, libido, sexual 
function, energy levels, sense of well being, and muscle mass and strength. (2|⊕⊕OO) 
 
Evidence 
Central hypogonadism in males leads to adverse manifestations and sequelae, which T replacement 
may reverse. Studies on this topic are limited in that they employed various T formulations with different 
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regimes, were usually short duration with a small number of patients, and were not randomized placebo-
controlled.  
 
Treatment increases BMD (132-135) and improves trabecular structure (136) and bone mechanical 
properties (137). Nevertheless, data on the impact on fracture risk are not currently available. 
 
T replacement increases libido, sexual motivation and sexual function (134,135,138-143), mood 
(144), sense of well being, concentration (135,139,143,145-147), self-reported sense of energy (134,135), 
muscle mass and strength (132,148,149), and the recovery of anemia related to T deficiency (134). Men 
with non-replaced hypogonadism due to non-functioning pituitary adenomas scored significantly worse in 
parameters of health-related QOL questionnaires compared to those with an intact gonadotroph axis or on 
hormone replacement (37).   
 
Choice of T formulations depends on numerous factors including the risk of specific adverse effects, 
the cost, patient convenience, and patient preference. For information regarding T therapy, potential 
adverse effects, available T formulations, and treatment monitoring (150), we recommend the most recent 
Endocrine Society guidelines (95). 
 
Estrogen Replacement in Premenopausal Women 
2.10 We recommend gonadal hormone treatment in premenopausal women with central 
hypogonadism, provided there are no contraindications. (1|⊕⊕⊕O) 
 
Evidence 
For premenopausal women with central hypogonadism, clinicians should prescribe gonadal hormone 
replacement (unopposed estrogens for women who have undergone hysterectomy, or combined estrogen-
progestogen preparations for those with an intact uterus to prevent endometrial hyperplasia).  
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Studies, primarily in women close to or after the natural age of menopause, have shown that oral 
estrogen or combined estrogen/progestogen therapy are very effective in alleviating vasomotor symptoms 
of hypoestrogenism (hot flushes and night sweats) (151) and improving vaginal atrophy (152), urinary 
frequency, and dysuria (153). As there are no studies on premenopausal women with central 
hypogonadism, for this group of female patients clinicians often refer to the published results from 
women with primary hypogonadism.  
 
Treatment with estrogens until age 45 years or longer may reduce the risk of cardiovascular disease 
and mortality (47,49,51).  
 
Primary ovarian failure is associated with reduced BMD and increased risk of fractures (154-156), 
and estrogen replacement protects against fractures (154,157,158). Other pituitary hormone deficits 
and/or their treatment also affect BMD and the risk of fracture in central hypogonadism (131,159,160). 
Studies assessing the clear impact of estrogen treatment on fracture risk are not available. Nonetheless, 
the literature on primary ovarian failure supports the beneficial effects of estrogen on bone. Furthermore, 
clinicians should prescribe other general measures optimizing BMD (including lifestyle changes, weight-
bearing exercises, adequate calcium and vitamin D supplementation, and avoiding smoking).  
 
Remarks 
The combined estrogen-progestin contraceptive pill (compared with HRT) may be more acceptable 
for younger females; however, studies comparing effects of these two regimes in central hypogonadism 
are lacking.  
 
Estrogens are available in many forms with different potency (oral, transdermal, topical gels and 
lotions, intravaginal creams and tablets, and vaginal rings). The choice of the estrogen (and progestin) 
preparation relies on the risk of adverse effects, cost, patient convenience, and patient preference.  
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Follow-up of gonadal hormone replacement includes evaluating symptoms and monitoring for side 
effects. Measuring serum E2 levels is not beneficial; moreover, some estrogens are not detected by the 
assays. 
 
Studies have not associated HRT in women 40-49 years with increased risk of breast cancer (161), 
and there is no evidence that estrogen replacement in women with premature ovarian failure relates to a 
higher risk of breast cancer (162).  
 
It is prudent to replace gonadal hormones until the mean age of natural menopause (163).  
 
Growth Hormone Replacement Therapy 
2.11 We recommend offering GH replacement to those patients with proven GHD and no 
contraindications. We recommend a starting dose of 0.2-0.4 mg/day for patients younger than 60 years 
and 0.1-0.2 mg/day for patients older than 60 years. (1|⊕⊕⊕O) 
 
2.12 We recommend titrating GH doses and maintaining IGF-1 levels below the upper limit of 
normal and reducing the dose if side effects manifest. (1|⊕OOO) 
 
2.13 We suggest against administering GH to elderly adults with age-adjusted low IGF-1 levels and 
no history of pituitary or hypothalamic disease. (2|⊕OOO)  
 
2.14 We recommend against using GH to enhance athletic performance, as this practice is illegal in 
the U.S., has poor scientific or ethical justification, and does not have substantiated efficacy. (Ungraded  
good practice statement) 
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Evidence 
GH therapy is approved for replacement in adults with rigorously proven GHD or for treating HIV-
related muscle wasting (164). Younger patients require higher doses, especially if serum IGF-1 levels are 
particularly low.  
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Table 5. Growth Hormone Replacement Therapy for Adult Growth Hormone Deficiency  
 
 
 
Patient Monitoring After Initiating Adult GH Replacement 
 
1. Measure IGF-1 6 weeks after initiating GH replacement, after dose escalations, and   
every 6 months thereafter. 
2. Assess body weight, blood pressure, waist circumference, and BMI every 6 months. 
3. Assess thyroid and adrenal function, and replace or adjust replacement doses as  
indicated. 
4. Assess metabolic profile including blood sugar and lipids every 6 months. 
5. Assess BMD by DXA annually. 
6. Periodically assess residual pituitary mass via a pituitary MRI.  
7. Assess QOL.  
Abbreviations: DXA, dual-energy x-ray absorptiometry; MRI, magnetic resonance imaging; BMI, body mass index; 
QOL, quality of life; BMD, bone mineral density [Derived from Melmed S: Endocrine Society: Idiopathic adult growth 
hormone deficiency. J Clin Endocrinol Metab. 2013; Jun;98(6):2187-97.doi: 10.1210/jc.2012-4012.] 
   
 
Starting Dose 
Age <60 years 
Age >60 years 
Mg/Day 
0.2-0.4 
0.1-0.2 
Dose Titration 
Increase by 0.1-0.2 mg/day 
 
6-week intervals 
 
Dose Determinants 
Mid-normal age-adjusted IGF-1 level 
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 Initial low GH replacement doses are preferred as fluid retention is dose-dependent. As women 
exhibit features of relative GH resistance, they usually require higher starting and maintenance 
replacement GH doses, as do women receiving oral estrogens (165). Morbid obesity may also require 
increased GH dosing.   
 
Remarks 
Once the dose has been stabilized, clinicians should monitor for efficacy. The effects of appropriate 
GH replacement usually manifest within 6 weeks of initiating therapy, but may require a longer time 
period for maximum benefit. 
 
Overall, GH replacement results in improved lipoprotein metabolism, body composition, and BMD. 
Visceral adipose tissue mass is decreased by 9% in female patients receiving GH replacement (166), 
while lean body mass improves by up to 7% during the first year of GH replacement (167,168). Muscle 
strength improvement is sustained for at least 10 years (168). A meta-analyses of 11 randomized trials 
reported that adult GH replacement resulted in significantly enhanced maximum oxygen uptake and 
muscle power (169). Although the beneficial effects of weight loss confound the impact of GH on insulin 
sensitivity, GH itself is an insulin-antagonist. Serum lipoprotein profiles improve with reduced total and 
LDL cholesterol and increased high-density lipoprotein (HDL) cholesterol, triglycerides, and ApoB 100 
levels (170). Lean body mass cardiac stroke volume and left ventricular mass are increased (170). 
However, research has not consistently reported cardiovascular risk profile improvement (171). The 
effects of GH replacement on BMD are more beneficial in men (172) and with patients that have severe 
bone loss. Increased bone mass occurs after 12 months (173), and fracture development is slowed in 
patients with no previous osteoporosis (159).  
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Side effects of GH replacement at the recommended doses manifest in about 20% of patients and are 
usually reversible by lowering the GH dose. Reported side effects include fluid retention, arthralgias, 
myalgias, paresthesias, carpal tunnel syndrome, sleep apnea, sleep disturbances, and dyspnea. If 
replacement doses are too high, insulin resistance with diabetes may occur. Although the development of 
new cancers and new-onset diabetes are of concern, the safety profile for GH treatment (using appropriate 
replacement doses) appears favorable in long-term surveillance studies (174). GH administration does not 
appear to increase the rate of pituitary adenoma recurrence (RR 0.887, 95% CI, 0.56-1.33) (175)(Jasim, S; 
A systematic review and meta-analysis, JCEM [In Press]).  
 
Diabetes Insipidus  
2.15 When administering DDAVP in DI, we suggest individualized therapeutic schedules. While 
clinicians should offer therapy to all patients, some patients with partial DI may not be bothered by 
polyuria and may prefer no treatment. To reduce the risk of hyponatremia, we recommend that clinicians 
educate all patients receiving DDAVP about the risk of overdosing. Periodically (at least weekly), 
patients should experience a phase of polyuria during which the effect of the medication has obviously 
worn off. (Ungraded good practice statement) 
 
2.16 In post-pituitary surgery DI, we suggest that clinicians should make at least one attempt to 
discontinue DDAVP during the weeks to months after surgery to determine if posterior pituitary function 
has recovered. (Ungraded good practice statement) 
 
2.17 In cases of adipsic DI, we suggest careful DDAVP and fluid intake titration that includes 
frequent weighing and serum sodium level monitoring. (Ungraded good practice statement) 
 
2.18 We suggest that all patients with DI wear an emergency bracelet or necklace to inform clinicians 
of the patient’s health problem if incapacitated. (Ungraded good practice statement) 
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Evidence 
 DDAVP, a longer-acting analog of ADH, acts mostly on the V2 receptor and thus has only minimal 
vasopressor activity. When treating DI patients in the outpatient setting who have an intact thirst 
mechanism, clinicians should use the lowest DDAVP dose that allows adequate rest at night and causes 
minimal disruption of individual daytime activities. About one quarter of DI patients with an intact thirst 
mechanism who are treated with DDAVP have mild hyponatremia caused by the inability to reverse the 
antidiuretic effect of the drug when fluid intake exceeds requirements (176). Because of differences in 
work or travel schedules, and because of the high variability of medication response (177), clinicians 
must individualize and tailor treatments to meet patient requirements and practical needs.  
 
Clinicians can administer DDAVP subcutaneously, orally, intra-nasally, or sublingually as a melt (the 
latter form is not available in all countries). In all forms, clinicians must carefully monitor treatment to 
prevent overdosing, which can result in potentially dangerous hyponatremia (178). This is particularly 
important in elderly individuals who may have increased renal sensitivity to the drug and/or may have 
abnormalities in osmoregulation (179). Oral and sublingual DDAVP absorption rates are <1%, while 
intranasal is ~6% (180). Oral DDAVP is available in 100, 200, and in some countries 400 mcg tablets. 
Sublingual melts and nasal preparations include a spray (usually 10 mcg per squirt) and a rhinyl tube 
(dose range 1-10 mcg). The mean dose ratio of sublingual to intranasal DDAVP is 1:24 (181); we list  
dose comparisons in Table 6.  
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Table 6. Dose Comparisons of Available Desmopressin Formulations  
 Melts Tablets Spray Drops Injections 
Bioavailability 0.25% (CI 
0.21-0.31%) 
0.16±0.17% 6.0±2.29% Similar to 
spray? 
NA 
Dose 
Equivalence 
60 µg 
120 µg 
240 µg 
100 µg 
200 µg 
400 µg 
2.5 µg 
5.0 µg 
10.0 µg 
2.5 µg 
5.0 µg 
10.0 µg 
NA 
<0.5 µg 
<1.0 µg 
 Abbreviations: ?, unclear; NA, not applicable [Adapted from Oiso,Y., Robertson,G.L., Norgaard,J.P., & Juul,K.V. 
(2013) Clinical review: Treatment of neurohypophyseal diabetes insipidus. J.Clin.Endocrinol.Metab 98, 3958-3967, 
with permission, © Endocrine Society (180).] 
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 Sometimes hypothalamic pathology or surgery may alter the thirst mechanism due to damaged 
hypothalamic osmoreceptors. In these cases there is high risk of both hypernatremia and hyponatremia, as 
patients cannot adjust fluid intake according to thirst (176). After careful titration (requiring frequent 
weighing and sodium measurements), we suggest a fixed dose of DDAVP and a constant amount of fluid 
intake together with consistent environmental temperature and humidity conditions (182). 
 
Interactions Between Replacement Hormones  
Glucocorticoids and Growth Hormone  
2.19 We suggest testing HPA axis functionality before and after starting GH replacement in patients 
who are not receiving GC replacement and who have demonstrated apparently normal pituitary-adrenal 
function. (2|⊕OOO) 
 
Evidence 
Many features of hypopituitarism, such as visceral obesity, insulin resistance, osteoporosis, and 
increased vascular mortality are reminiscent of Cushing’s syndrome (183,184). Patients with GHD in the 
setting of hypopituitarism demonstrate an increased cortisol/cortisone metabolite ratio (185,186).  
 
As GH suppresses the conversion of cortisone to cortisol, patients receiving GC replacement may 
require higher doses once GH is initiated, and those with low adrenal reserve may be rendered hypo-
adrenal by the GH therapy (183,187). 
 
Glucocorticoids and Thyroid 
2.20 We suggest evaluating patients with CH for AI prior to starting L-T4 therapy. If this is not 
feasible, clinicians should prescribe empiric GC therapy in patients with CH who are starting L-T4 
therapy until there is a definitive evaluation for AI. (2|⊕⊕OO) 
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Evidence 
Data suggest that AI should be conclusively excluded prior to initiating L-T4 therapy for CH. This is 
because thyroid hormone accelerates endogenous cortisol clearance and could unmask insufficient 
cortisol production and precipitate AC. If patients start L-T4 therapy prior to evaluation, clinicians should 
initiate empiric GC replacement therapy simultaneously until they complete a definitive evaluation for AI 
(33). 
 
Physiologic and pharmacologic doses of GC suppress TSH levels (188). CH patients receiving GC 
therapy do not appear to require L-T4 dose adjustments (77).   
 
Glucocorticoids and Estrogen  
2.21 We suggest that when clinicians assess adrenal reserve or the adequacy of HC replacement they 
take into consideration that total serum cortisol level can be elevated due to the effects of estrogen on 
CBG. (2|⊕⊕⊕O) 
 
Evidence 
About 95% of circulating cortisol is bound mainly to CBG and to a lesser extent to albumin, and 
unbound cortisol is the active fraction. Oral estrogen therapy increases circulating CBG (through a 
hepatic first-pass effect), leading to increased total cortisol levels; this does not occur with transdermal 
estrogen therapy (189,190).  
 
Growth Hormone and Thyroid 
2.22 We recommend that clinicians monitor euthyroid patients with GHD who begin GH therapy for 
the risk of developing CH, and if fT4 levels decrease below the reference range, these patients should 
begin L-T4 therapy. CH patients with GHD who are already receiving L-T4 may require increased L-T4 
doses when they begin GH therapy to maintain fT4 levels within target ranges. (1|⊕⊕OO) 
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2.23 We suggest clinicians treat CH before performing GH stimulation testing, because CH may 
impair the accurate diagnosis of GHD. (2|⊕⊕OO)  
 
Evidence 
Administering GH to GHD adults causes variable changes in thyroid hormone levels—the most 
consistent effect being decreased fT4 levels (81,191,192). Some studies also report increased fT3 levels 
with no significant effects on TSH levels. These effects can decrease fT4 levels into the hypothyroid 
range, suggesting that untreated GHD can mask CH by artificially maintaining fT4 levels in the reference 
range. In patients with GHD, 36-47% of euthyroid patients and 16-18% of treated CH patients developed 
low fT4 levels within 3-6 month of starting GH therapy (191,193). Most patients, who were at increased 
risk of developing CH while receiving GH and who had previously undergone surgery and/or radiation 
therapy for pituitary tumors, had lower basal T4 levels and were more likely to have other multiple 
hormone deficiencies. Clinicians should monitor GHD patients for developing CH approximately 6 weeks 
after they start or adjust GH therapy (194). Alexopoulou et al. reported that only men with CH required 
increased L-T4 doses after starting GH therapy (1.8 vs. 1.6 mcg/kg/day) (77).  
 
The hypothalamic-pituitary-thyroid axis also influences GH dynamics, with altered GH and IGF-1 
secretion occurring in hypothyroidism (34). IGF-1 levels are reduced in hypothyroidism, and GH 
stimulation with insulin or GH-releasing hormone may be blunted (185,195). Clinicians could over-
diagnose GHD in the setting of CH and should treat CH prior to performing stimulation tests for GHD. 
 
Estrogen and Thyroid Hormones 
2.24 In patients with CH requiring changes in estrogen therapy, we recommend monitoring fT4 levels 
and adjusting L-T4 doses to maintain fT4 levels within target ranges. (1|⊕⊕⊕O) 
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Evidence 
Increased serum estrogen levels, whether endogenous (pregnancy), or exogenous (estrogen 
replacement therapy, oral contraceptives), result in increased L-T4 dose requirements in patients with 
primary hypothyroidism (196). This is due to the estrogen-dependent liver production of thyroid-binding 
globulin (TBG). Estrogen therapy increased mean L-T4 dose requirements in patients with CH from 1.3 
to 1.8 mcg/kg/day (77).   
 
Growth Hormone and Estrogen  
2.25 We suggest that women on oral estrogen replacement receive higher GH doses compared with 
eugonadal females or males. (2|⊕⊕⊕O) 
 
Evidence 
Oral estrogen treatment leads to decreased circulating IGF-1 levels in GHD women resulting in 
increased postprandial lipid oxidation and decreased protein synthesis, which antagonizes the metabolic 
actions of GH. This does not occur with transdermally-administered estrogen, suggesting a first-pass 
effect of estrogen and the inhibition of hepatic GH actions (197-199). One study showed that women on 
oral estrogen might require a GH replacement dose up to 50% higher compared with women or men who 
are not on estrogen (199). 
 
Glucocorticoids and Diabetes Insipidus 
2.26 Because AI may mask the presence of partial DI, we suggest monitoring for the development of 
DI after starting GC replacement. Conversely, patients with improved DI without an AI diagnosis should 
undergo AI testing. (2|⊕OOO) 
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Evidence 
GC deficiency induces impaired free renal water clearance, resulting in the masking of polyuria in DI 
(200). 
 
Risk of Hormonal Over-Replacement in Hypopituitarism  
Bone Disease 
2.27 Clinicians should individually assess GC replacement and avoid over-replacement to reduce the 
risk of osteoporosis. We suggest low-dose HC replacement, since this approach might be associated with 
increased bone formation and a positive bone remodeling balance. (2|⊕⊕OO) 
 
2.28 In men with hypopituitarism over-replaced with GC and at risk for fractures, we suggest 
vertebral fracture assessment (baseline plain spinal X-rays or dual-energy X-ray absorptiometry) to 
identify patients with unsuspected vertebral fractures. (2|⊕⊕OO) 
 
2.29 We suggest clinicians monitor L-T4 replacement, as recommended in previous sections, and 
avoid over-replacement to reduce the risk of fractures. (2|⊕⊕OO) 
 
Evidence 
Very few studies have assessed the impact of GC dose optimization on markers of bone formation 
and resorption (120). 
 
A post-hoc analysis (201) from a prospective single-center study on 175 adult patients with 
hypopituitarism (including GHD) showed that patients with AI receiving near physiological doses of HC 
did not exhibit a greater therapeutic response to GH than their counterparts not on GC replacement. In 
patients with AI on three different replacement regimens (for at least 4 weeks), replacement was 
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associated with low serum ionized calcium levels without any evidence of compensatory increased 
parathyroid hormone (PTH) levels; this was consistent with the direct or indirect suppression of bone 
remodeling and suppression of PTH levels (202). 
 
Another small open crossover study in hypopituitary men randomized to three commonly used HC 
dose regimens reported that low-dose HC replacement (10 mg a.m. and 5 mg p.m.) was associated with 
increased bone formation and positive bone remodeling balance and with probable long-term beneficial 
effects on bone health. (203) 
 
Over-replacement with GC in male patients with pituitary dysfunction can increase vertebral fracture 
risk, despite the restoration of gonadal status. In a cross-sectional study (160) of male hypopituitary 
patients receiving a median daily doses of HC 30 mg and cortisone 35  mg, 60% of patients had vertebral 
fractures. The risk of fracture correlated with untreated GHD, urinary cortisol values, and cortisone doses. 
In patients on GH replacement, neither cumulative or current cortisone doses influenced the prevalence of 
vertebral fractures.  
 
L-T4 over-replacement in patients with primary hypothyroidism may increase bone turnover and 
increase the fracture risk, especially in postmenopausal women. Similarly, in a cautionary study in 74 
adult CH patients treated with 1.1 mcg/kg/day L-T4, higher daily L-T4 doses were associated with a 
higher prevalence of vertebral fractures (assessed by lateral spine x-rays) (131). This finding raises the 
question of possible adverse effects associated with targeting higher fT4 levels. Clinicians should monitor 
CH patients for developing low bone mass, although there are no studies that assess the risks and benefits 
of adjusting L-T4 doses in CH based on bone health in addition to other clinical parameters. 
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Cardiovascular Risks in Patients with Hypopituitarism on Replacement Therapy 
Glucocorticoid Over-Replacement  
2.30 In patients with central AI, we recommend using the lowest tolerable dose of HC replacement to 
potentially decrease the risks of metabolic and cardiovascular disease. (1|⊕⊕⊕O) 
 
Evidence  
Higher GC replacement doses in patients with ACTH deficiency are associated with increased overall 
and cardiovascular mortality; the greatest risk is in patients receiving daily HC doses higher or equal to 30 
mg (8). This highlights the importance of providing patients with an adjustable GC replacement therapy 
regimen (204). 
 
In a randomized crossover study (205), peripheral and hepatic insulin resistance did not differ 
between patients treated with HC twice daily (15 mg with breakfast, 5 mg with evening meal) versus 
those receiving physiological HC infusions. Short-term GC replacement increase (7-day increase in HC to 
30 mg/day) (206) resulted in reduced endothelial function and improved left ventricular systolic loading. 
Endothelial dysfunction, likely a direct effect of higher GC doses, may contribute to excess 
cardiovascular mortality in treated ACTH-deficient patients (207). It has been also been suggested that 
lower HC doses (15 mg HC per day) may result in lower arterial stiffness and a more physiological 
nocturnal blood pressure dip (208). 
 
Dose reduction might also be associated with clinical improvement. When patients cut their GC dose 
in half (from 20-30 mg to 10-15 mg HC daily), mean body weight decreased by 7.1 kg after 6-12 months 
(209). Whereas, a small prospective study of patients with hypopituitarism taking 30 mg HC did not 
report improvements in weight, 24-hour urine-free cortisol, glucose, or HbA1C (210).  
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Patients with partial central AI might be more likely to be over-treated. There is no apparent dose-
dependent difference in integrated cortisol daily curves between patients on half-dose or no HC 
replacement (211), suggesting that current conventional full GC replacement doses might over-treat 
patients with partial ACTH deficiency. 
 
Due to the known increased risk of thromboembolism in patients with Cushing’s syndrome, it is 
presumed that non-physiological GC replacement regimens might contribute to this risk. However, when 
comparing low-dose versus high GC regimens (17.5 mg HC vs. 30 mg daily) for 2 weeks, fibrinolytic-
coagulation parameters did not change (212). 
 
Thyroid Replacement 
2.31 To avoid the possible long-term cardiovascular risks of insufficient or excess thyroid hormone 
treatment, clinicians should adjust L-T4 doses to avoid low or elevated fT4 levels in CH. (Ungraded  
good practice statement) 
 
Remarks 
The long-term cardiovascular risks of CH have not been well studied. However, recent evidence 
suggests that mild hyperthyroidism or hypothyroidism may increase overall and cardiovascular-specific 
mortality and morbidity (213-218). 
 
Estrogen and Testosterone Replacement 
The overall impact of estrogen and T replacement on cardiovascular disease in patients with central 
hypogonadism is unclear.   
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Treatment with estrogens through age 45 years or longer may reduce the risk of cardiovascular 
disease and mortality (47,49,51). Results of the Women’s Health Initiative (average participant age 63 
years) showed that combined hormone therapy increases the risk of cardiovascular events. However, we 
cannot extrapolate these results to younger women with premature ovarian failure (219). 
 
T therapy in males with central hypogonadism reduces fat mass and increases fat-free mass 
(132,135,140,148,149). An analysis of 19 studies on the effects of administering T esters intramuscularly 
(220) reported a small, dosage-dependent decrease in HDL cholesterol and a concomitant reduction in 
total and LDL cholesterol. Given the lack of long-term randomized placebo controlled trials in males with 
central hypogonadism, the overall impact of T replacement on cardiovascular disease or mortality is 
unclear.   
 
3. Special Circumstances 
Cushing’s Disease  
3.1 We recommend GC replacement until full HPA axis recovery after surgically resecting ACTH-
secreting tumors. (1|⊕⊕⊕O) 
 
3.2 After curative surgery for Cushing’s disease, we recommend retesting thyroid and GH axes before 
starting replacement treatment. (1|⊕OOO) 
 
Evidence 
ACTH excess from a pituitary tumor will suppress normal pituitary corticotroph cells, and AI can 
persist for years after surgical tumor resection. Hormonal replacement after curative surgery for 
Cushing’s disease has been recently reviewed in an Endocrine Society guideline (221). In 16 studies 
assessing the recovery of adrenal function after successful treatment for Cushing’s disease (112), most 
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patients recovered HPA axis by 2 years. We recommend GC replacement until full HPA axis recovery 
(112,114).  
 
In the context of multiple pituitary deficiencies associated with Cushing’s disease (222,223), 
clinicians should re-assess the need for hormonal replacement (thyroid, GH) after surgery, and should not 
start replacement before repeat testing of the HPA axis (221). 
 
Prolactinomas 
3.3 We recommend reassessing the gonadotroph axis in patients with macroprolactinoma and central 
hypogonadism who have had successful dopamine agonist treatments. (1|⊕⊕⊕O)  
 
Evidence 
Administering dopamine agonists to patients with macroprolactinoma leads to normoprolactinemia in 
68% (range 40-100%) and tumor shrinkage in 62% (range 20-100%) (224). Studies have reported that 44-
62% of cases experience a reversal of hypogonadism, usually within 6 months after starting treatment 
(225,226). Further research has reported the recovery of other hormonal axes following adenoma 
shrinkage (227); therefore, patients should have hormonal re-evaluation to avoid unnecessary life-long 
hormone replacement.  
 
GH Replacement in Cured Acromegaly after Surgery and/or Radiation 
3.4 We suggest low-dose GH replacement in patients with cured acromegaly and documented GHD 
in the absence of known contraindications. (2|⊕OOO)  
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Evidence 
Acromegaly patients, after rigorous GH dynamic testing and documentation of GHD, may benefit 
from low-dose GH replacement (228). Features of accelerated GHD may develop in acromegaly patients 
who have had a GH-secreting adenoma surgically resected. In these patients, immediate (72 hours) post-
operative GH levels, as well as the bilaterality of intrasellar tumor involvement, are significant 
determinants of subsequent GHD (seen in about 10% of patients) (229). In a large retrospective analysis, 
overall mortality was similar; however, cardiovascular mortality was higher in GHD associated with 
treated acromegaly versus GHD associated with non-functioning pituitary adenomas (SMR 3.03, p < 
0.02) (230). 
 
In a randomized placebo-controlled study, mean GH doses of 0.58 mg/day resulted in decreased 
visceral fat mass and improved QOL indices (231). A prospective study of 42 subjects reported that GH 
replacement enhanced QOL and improved both body composition and lipid profiles (232). These benefits 
appear to occur without incurring the risk of glucose intolerance.  
 
Perioperative Management of Hypopituitarism  
Pituitary Surgery 
3.5 We recommend using stress doses of steroids in AI before surgery and tapered doses after surgery 
before repeating testing. (1|⊕⊕⊕O) 
 
3.6 In patients with normal preoperative adrenal function, we suggest an individualized clinical 
approach for postoperative GC administration until the HPA axis can be evaluated. (2|⊕⊕OO) 
 
3.7 With preoperative CH, we recommend using L-T4 therapy before non-emergency surgery and 
throughout the perioperative period. (1|⊕⊕⊕O) 
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3.8 With intact preoperative thyroid function, we recommend measuring fT4 levels 6-8 weeks post-
operatively to assess for CH. (1|⊕⊕OO) 
 
3.9 We suggest that initial therapy for DI utilizes short-acting subcutaneous aqueous ADH, allowing 
for safer use in the vast majority of cases in whom DI resolves spontaneously. (2|⊕⊕OO) 
 
3.10 We do not suggest pre-scheduled DDAVP dosages in the first week post-surgery because of the 
risk of hyponatremia after transient DI resolves and the risk of SIADH that may occur 7-10 days after 
surgery. (2|⊕OOO) 
 
3.11 We suggest oral or intranasal DDAVP after discharge, with clear instructions that patients 
should only use the medication if significant polyuria occurs. (2|⊕OOO) 
 
3.12 We suggest retesting all pituitary axes starting at 6 weeks after pituitary surgery and then 
periodically to monitor the development or resolution of pituitary deficiencies. (2|⊕⊕OO) 
 
Evidence 
Pituitary adenomas, as well as the associated surgical and radiation treatments, can cause 
hypopituitarism. Rates of pituitary axes recovery or new onset hypopituitarism after transsphenoidal 
surgery vary significantly between studies (115,233,234).  
 
A meta-analysis showed that morbidity of early postoperative AI ranged from 0.96-12.90%, with an 
overall morbidity of 5.55% (235). 
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Depending on circumstances, clinicians start stress doses of GC before surgery in patients with 
preoperative AI. Stress doses are tapered after surgery and discontinued if repeat testing shows a normal 
HPA axis. In patients with normal preoperative adrenal function, clinicians often prescribe GC in the 
immediate postoperative period until the HPA axis can be evaluated (115,233,234).   
 
However, a postoperative morning cortisol level higher than 15 mcg/dL may mitigate the requirement 
for postoperative GC treatment (236). A morning cortisol  measurement might be useful even after 
intraoperative administration of dexamethasone (237). Other steroid-sparing regimens have also been 
suggested (Xiaolin, Jia; Utility of a glucocorticoid sparing strategy in the management of patients 
following transsphenoidal surgery [In Press]) but further research is needed, especially for patients that 
are discharged from the hospital on postoperative day 1.  
 
Clinicians should treat preoperative CH with L-T4. If surgery is not urgent, it may be optimal to wait 
until CH is adequately treated to optimize surgical outcomes, however perioperative complications seem 
to be minor (238,239). Patients should continue replacement L-T4 throughout the perioperative period 
and have fT4 levels checked 6 weeks after surgery to gauge the adequacy of the L-T4 dose. If patients do 
not start L-T4 preoperatively or continue L-T4 postoperatively, clinicians should evaluate patients for CH 
by measuring fT4 levels 6-8 weeks following surgery since the serum half-life of T4 is 7 days. 
 
DI occurs commonly in the immediate period (day 1-2) after pituitary or hypothalamic surgery (240). 
Other causes of postsurgical abundant diuresis include steroid-induced hyperglycemia, abundant 
intraoperative fluid administration, and (in the case of acromegaly) an abrupt reduction of serum GH 
levels (241). High-dose perioperative GCs increase the incidence of postoperative DI, possibly mediated 
by an increased glomerular filtration rate (242), reduced ADH secretion, and reduced renal sensitivity to 
GCs (243-245). 
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The risk of developing new-onset, postoperative pituitary failure depends on tumor size, surgical 
expertise, and the extent of surgery (246). 
 
Non-Pituitary Surgery 
3.13 On the day of surgery, we recommend adjusting GC doses according to the severity of illness 
and magnitude of the stressor. (1|⊕⊕⊕O) 
 
3.14 In cases of minor to moderate surgical stress, we suggest 25-75 mg HC per 24 hours (usually for 
1-2 days). (2|⊕⊕OO) 
 
3.15 In cases of major surgical stress, we suggest a 100 mg HC per IV injection followed by a 
continuous IV infusion of 200 mg HC per 24 hours (alternatively 50 mg q6h IV or IM). (2|⊕⊕OO) 
 
Evidence 
Adults secrete 75-100 mg of cortisol per day in response to major surgery and 50 mg per day in 
response to minor surgery (247). Cortisol secretion in the first 24 hours after surgery rarely exceeds 200 
mg and correlates with the duration and extent of surgery (247). Studies have suggested lower doses of 
HC (25-75 mg/24 hour) for surgical stress in secondary AI (247,248).  
 
Management of Hypopituitarism in Pregnancy  
As fertility is often impaired in hypopituitarism, natural pregnancy is rare. Women require a 
multidisciplinary team for fertility induction and the management of hypopituitarism. However, with 
appropriate hormonal replacement, women with hypopituitarism can expect an uneventful pregnancy and 
a healthy infant. 
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Glucocorticoids 
3.16 We suggest using HC as the preferred GC in pregnancy and increasing the dose based on the 
individual clinical course; higher doses may be required, in particular during the third trimester. 
(Ungraded good practice statement) 
 
3.17 We suggest that pregnant patients with central AI be closely monitored for clinical symptoms 
and signs of glucocorticoid over- and under-replacement (e.g., normal weight gain, fatigue, postural 
hypotension or hypertension, hyperglycemia). (Ungraded good practice statement) 
 
3.18 We recommend against using dexamethasone in pregnancy, because it is not inactivated in the 
placenta. (1|⊕⊕OO) 
 
3.19 We recommend HC stress dosing during the active phase of labor, similar to that used in major 
surgical stress. (1|⊕⊕OO) 
 
The diagnosis of AI may be missed in the first trimester due to confounding symptoms of normal 
pregnancy. A low morning cortisol <3 ug/dL in the presence of typical clinical presentation is diagnostic 
of AI (249). Plasma cortisol can be falsely “normal” because of increased CBG in the second and third 
trimesters (250). One study suggests new normal ranges for cortisol in pregnancy (251).  
 
HC is the preferred physiologic GC replacement in pregnancy as it is degraded by the enzyme 11beta-
HSD2 and does not cross the placenta.  
 
The best regimen of GC replacement in pregnancy is not well defined; therefore, we recommend 
adjusting dose regimes based on clinical judgment. Another approach is to increase HC doses by 20-40% 
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in the third trimester (16,72). Lower doses of HC might be needed in women with hypopituitarism 
(compared with primary AI) who are not treated with GC replacement (28,110,112,183,184). 
 
During labor and delivery, clinicians should administer a stress dose of GC (50 mg IV HC in the 
second stage of labor). For cesarean section, we recommend a dose of 100 mg every 6-8 hours (28,250). 
Endocrine Society guidelines reviewed the management of primary AI in pregnancy (72). GC 
recommendations are relatively similar in central AI and primary AI; however, patients with central AI do 
not require mineralocorticoid replacement.   
 
Thyroid  
3.20 We recommend that clinicians monitor fT4 or total T4 levels every 4-6 weeks for women with 
CH who become pregnant, and that these women may require increased L-T4 doses to maintain levels 
within target ranges for pregnancy. (1|⊕⊕OO)  
 
Evidence 
Treating hypothyroidism is critical for optimal pregnancy outcomes and fetal brain development. 
Many women with primary hypothyroidism require significant (20-50%) increases in L-T4 doses early in 
pregnancy to maintain normal thyroid hormone levels (196) due to increased TBG levels secondary to 
high serum E2 levels. Current recommendations include increasing L-T4 doses by two extra pills per 
week (based on previous dose) upon confirming pregnancy and making further dose adjustments based on 
thyroid hormone and TSH levels. However, women with CH may not require the same degree of L-T4 
dose escalation due to human chorionic gonadotropin stimulation of an intact thyroid gland (at least 
during the first trimester). It is prudent to monitor pregnant women with CH closely with L-T4 dose 
adjustments based on thyroid hormone levels. It should be noted that many fT4 assays do not perform 
well during pregnancy; if pregnancy-specific fT4 reference ranges are not available, clinicians can use 
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total T4 reference ranges adjusted upward by 50% (196). Clinicians should reduce L-T4 doses back to 
pre-pregnancy levels immediately after delivery to avoid iatrogenic hyperthyroidism. 
 
In contrast to primary hypothyroidism, serum TSH levels in CH are not useful for monitoring L-T4 
doses in pregnancy. Therefore, clinicians should use either fT4 or total T4 levels, depending on local 
experience with fT4 assay performance in pregnant patients. Many fT4 assays from pregnant patients are 
imprecise; an alternative approach is to monitor total T4 levels, adjusting the non-pregnant reference 
range upward by 50% to account for TBG effects (196). 
 
DDAVP 
3.21 In pregnant women with pre-existing DI, we suggest continuing DDAVP during pregnancy and 
adjusting doses if required. (2|⊕⊕OO) 
 
Evidence 
During pregnancy, serum sodium and osmolarity are reduced due to a decreased threshold for ADH 
release and thirst mechanism (252). The placenta produces large amounts of the enzyme vasopressinase, 
which degrades endogenous ADH and thus requires increased secretion. Pregnancy may unmask mild 
forms of DI, which often occurs with subsequent pregnancies.    
 
In general, the DDAVP requirement is unchanged, but it sometimes might be slightly higher (253). 
Exposure to DDAVP during pregnancy is safe (254), and DDAVP is generally considered safe for the 
newborn in lactating mothers (252).  
 
Growth Hormone  
3.22 We suggest discontinuing GH replacement during pregnancy, as there is no clear evidence yet 
for efficacy or safety, and the placenta produces GH. (2|⊕⊕OO)  
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Remarks 
An observational study on 201 pregnancies in hypopituitary patients reported that  >50% of patients 
continued GH replacement during pregnancy. GH use before and during pregnancy was not related to 
pregnancy outcomes; however, there are no prospective studies on this (255).  
 
Management of Hypopituitarism in Pituitary Apoplexy 
3.23 We recommend testing for acute pituitary insufficiency in all patients with pituitary apoplexy. 
(1|⊕⊕⊕O) 
 
3.24 As acute AI is a major cause of mortality, we recommend GC therapy until a laboratory 
diagnosis is established and the patient maintains normal pituitary function. (1|⊕⊕OO)  
 
3.25 We recommend that clinicians monitor pituitary axes in pituitary apoplexy patients treated with 
either surgical decompression or conservative management, as hypopituitarism may develop over time. 
(1|⊕⊕OO)  
 
Evidence 
Pituitary apoplexy is a life-threatening acute pituitary infarction, hemorrhage, and/or necrosis 
presenting as rapid onset headache, and may include vomiting, fever, meningismus, vision abnormalities, 
and changes in mental status (256). Partial or complete hypopituitarism is a prominent feature and 
contributes to high mortality (257,258). Pituitary apoplexy should be diagnosed early and treated 
promptly (259). 
 
Pituitary dysfunction may be due to preexisting deficiencies (20-22) or occurs quickly from a rapid 
increase of intrasellar pressure (257). Patients present with variable decreases in pituitary hormones; 
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however, DI is uncommon (257), with an incidence of 4% for transient and 2% for persistent DI. 
Differences in anterior and posterior pituitary blood supply may explain the relative sparing of ADH 
secretion (258).  
 
Transsphenoidal decompression and immediately instituting high-dose IV corticosteroid replacement 
therapy are the standard of care (260-262). However, we also advocate conservative management in a 
carefully selected group of patients (263).  
 
Recognizing acute secondary AI is critical, and patients should begin GC therapy promptly to prevent 
AC. High-dose GC may also improve visual outcomes (260). When patients cannot tolerate oral 
medications, they should begin with a 100-200 mg IV HC bolus followed by 2-4 mg/hour by continuous 
infusion or 50-100 mg injections every 6 hours (264). Clinicians should quickly taper HC as indicated and 
initiate standard oral maintenance dose. Clinicians have also used high doses of dexamethasone to treat 
pituitary apoplexy.  
 
Hypopituitarism may be permanent or transient after pituitary apoplexy, with recovery occurring from 
weeks to months from the initial event. (265) More than 50% of patients eventually require hormonal 
replacement (257,258,261). There is no consensus on whether surgical treatment improves pituitary 
function, but one study reported an increased incidence of hormonal deficiencies with conservative 
management (266). In one study of eight patients, transsphenoidal surgery achieved a return of normal 
pituitary function in most patients in the immediate postoperative period (257), although larger studies 
have not replicated these findings (263). Advocates of conservative management argue that there is no 
difference in long-term hypopituitarism rates between surgically managed and carefully selected, 
conservatively treated patients (263,267). 
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Treatment of Hypopituitarism in Patients Receiving Antiepileptic Medications 
3.26 We suggest clinicians educate AI patients that are taking non-dexamethasone GCs and who start 
enzyme-inducing AEDs about the early signs and symptoms of AI. (2|⊕⊕OO) 
 
3.27 In patients with AI on dexamethasone, we suggest increasing dexamethasone replacement doses 
if enzyme-induced AEDs are co-administered. (2|⊕OOO) 
 
3.28 In CH patients receiving L-T4, we recommend checking fT4 at least 6 weeks after starting an 
AED and increasing L-T4 doses if fT4 levels decrease below the target range. (1|⊕⊕OO) 
 
3.29 In women who have started estrogen replacement, we suggest evaluating AED levels and 
adjusting AED doses as required. (2|⊕⊕OO) 
 
3.30 We suggest monitoring DDAVP doses and making further adjustments as needed in patients 
who are started on AEDs. (2|⊕⊕OO) 
 
Evidence 
Some AEDs enhance hepatic CYP450 isoenzyme activity (e.g., phenytoin, carbamazepine, 
oxcarbazepine, and topiramade), accelerating the hepatic metabolism of hormonal preparations and 
decreasing serum concentrations of relevant hormones (268). Effects depend on the type of GC. 
Dexamethasone is metabolized primarily by hepatic CYP3A4 (269), and patients may need to increase 
dexamethasone doses (268). AEDs only modestly decrease the concentrations of prednisone and 
prednisolone (270). CYP3A4­mediated 6β­hydroxylation may not contribute significantly to the 
breakdown of cortisol; therefore, AEDs are less likely to be clinically significant in patients treated with 
HC (271-273). However, a recent report found that oxcarbazepine increases cortisol elimination in normal 
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subjects (272), suggesting that attention should also be paid to symptoms of underdosing in patients on 
HC. In conclusion, clinicians should always exercise caution when treating AI patients with any type of 
GC if patients are also taking AEDs. 
 
AEDs accelerate T4 and sex hormone clearance, and patients may require compensatory increases in 
hormone replacement doses (274). Some AEDs also displace thyroid hormones from their binding 
protein, resulting in observed normal or even decreased free hormone levels (275). As phenytoin may 
impair fT4 measurements, an equilibrium dialysis fT4 assay is preferred.  
 
Other AEDs increase SHBG, leading to the reduced bioavailability of E2 and T (268), which may 
compromise the efficacy of hormonal treatment. Combined estrogen and progesterone may decrease 
lamotrigine levels (276), and endogenous and exogenous sex steroids may affect seizure activity and 
epilepsy in women (277). 
 
The addition of carbamazepine, oxcarbazepine, lamotrigine, perapanel, or felbamate to DDAVP 
therapy can cause hyponatremia by increasing DDAVP renal responsiveness (268).  
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4. Appendices 
Appendix A: Assay characteristics of common automated immunoassays 
Hormone Assays 
Detectable 
Level 
Sample 
Stability 
Remarks Mean Variability  
(% Imprecision)  
at Stated 
Concentrations 
Within 
Method 
Between 
Methods 
GH 
(mcg/L) 
0.002   (b) 
0.01     (c) 
0.030   (d) 
Rfg. <8 hours. 
Frz. >8 hours 
(undetermined 
duration or 
about 2 
months). 
Avoid frz.-
thawing (activity 
lost after 
repeated 
cycles). 
Exhibits adequate 
assays sensitivity.  
Some assays (4) 
indicate detection of 
both 20 and 22 kDa 
forms. 
All assays use IRP 
98/574 (lower GH 
results when compared 
with earlier standard). 
Varied conversion 
factors were applied 
when converting 
mUnits/L to ug/L. All 
used BMI-related cut-
off values. Variability 
between assays was 
assessed at 3.4 ng/mL. 
6.9 % 23.1 % 
IGF-1 
(ng/mL) 
20       (c)  Rfg. <24 hours. 
Frz. up to 12 
months. 
 
It is preferable to 
measure IGF-BP-3 on 
the same sample. 
Variability between 
assays was assessed 
at 75 ng/mL. 
13.2% NA 
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Hormone Assays 
Detectable 
Level 
Sample 
Stability 
Remarks Mean Variability  
(% Imprecision)  
at stated 
concentrations 
Within 
Method 
Between 
Methods 
PRL 
(ng/mL) 
 
 
0.6       (a)  
0.25     (b) 
0.3       (c) 
0.047   (d) 
1.4       (e) 
RT <8 hours. 
If >24 hours 
(remove 
serum/plasma 
from gel/cells). 
Rfg. <48 hours 
(up to 7 days). 
Frz. up to 12 
months. 
Avoid repeated 
frz.-thawing.    
There is adequate 
agreement among 
assays (variability 
assessed at 7.2 
ng/mL). 
7.2% 
 
7.1% 
 
FSH 
(mIU/mL) 
 
 
0.05     (a) 
0.2       (b) 
0.3       (c) 
0.1       (d) 
0.66     (e) 
There is variability 
between assays 
(variability assessed at 
7.9 mIU/L). 
8.1% 
 
8.9% 
 
LH 
(mIU/mL) 
 
 
0.5       (a) 
0.2       (b) 
0.07     (c) 
0.1       (d) 
0.216   (e) 
There is variability 
between assays 
(variability assessed at 
3.9 mIU/L).  
7.7% 
 
8.9% 
 
TSH 
(mcIU/mL) 
 
 
0.0038 (a) 
0.015   (b) 
0.004   (c) 
0.005   (d) 
0.015   (e) 
There is variability 
between assays 
(variability assessed at 
0.73 mcIU/mL). 
6.1% 
 
8,3% 
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Hormone Assays 
Detectable 
Level 
Sample Stability Remarks Mean Variability  
(% Imprecision)  
at stated 
concentrations 
Within 
Method 
Between 
Methods 
fT4 
(ng/dL) 
 
 
0.4       (a) 
0.25     (b) 
0.1       (c) 
0.023   (d) 
0.07     (e) 
RT <8 hours. 
If >24 hours 
remove from 
gel/cells. 
Rfg. <48 hours (up 
to 7 days). 
Frz.  >48 hours (up 
to 30 days). Avoid 
repeated frz.-
thawing.  
There is variability 
between assays 
(variability 
assessed at 0.73 
ng/dL). 
12.2% 11.2% 
Estradiol 
(pg/mL) 
 
 
25       (a) 
20.0    (b) 
7         (c) 
5.0      (d) 
6.36    (e) 
RT <8 hours. 
If >24 hours 
remove from 
serum/plasma from 
gel / cells.  
Rfg. <48 hours (up 
to 7 days). 
Frz. Up to 6 
months.  
Avoid more than 
one freeze-thaw 
cycle. 
There is variable 
between assays 
(variability 
assessed at 141 
pg/mL). 
16.9% 64.9% 
T 
(ng/dL) 
 
 
4.33     (a) 
10.0     (b) 
10        (c) 
2.0       (d) 
4.9       (e) 
RT <8 hours. 
Remove from 
gel/cells 
immediately. 
Rfg. <48 hours (up 
to 7 days). 
Frz. Up to 60 days.  
Avoid more than 
one freeze-thaw 
cycle. 
There is high 
variability between 
assays (up to 54%) 
(variability 
assessed at 113 
ng/dL). 
11.4% 15.6% 
ADH     There are limited 
assays available. 
NA NA 
11- 
deoxycortisol 
  Rfg. if <7 days. 
Frz. If <14 days. 
 
An 8 a.m. 
specimen is 
preferred. 
NA NA 
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Hormone Assays 
Detectable 
Level 
Sample 
Stability 
Remarks Mean Variability  
(% Imprecision)  
at stated 
concentrations 
Within 
Method 
Between 
Methods 
Cortisol 
(micg/dL) 
1.0      (a) 
0.4      (b) 
0.2      (c) 
0.1      (d) 
0.16    (e) 
RT <8 hours.  
If >8 hours, 
remove 
serum/plasma 
from gel/cells. 
Rfg. <48 hours 
(up to 14 days).  
Frz. >48 hours 
(up to 30 days). 
There is adequate 
assays sensitivity for 
diagnosis. 
There is significant 
and variable cross-
reactivity with 
prednisolone and 
fludrocortisone. 
There is little or no 
cross reactivity with 
dexamethasone. 
Variability between 
assays was assessed 
at 4.1 mcg/L. 
9.5% 10.6% 
ACTH 
(pg/mL) 
 
1.0      (d) Collect sample 
in ice-cooled 
EDTA-tube. 
Centrifuge 
immediately in 
refrigerated 
centrifuge. 
Store frozen in 
plastic 
container (binds 
to non-
siliconized 
glass).  
Stable if frozen 
for 14 days. 
ACTH 1-24 
medication causes 
negative interference. 
Variability between 
assays was assessed 
at 17.4 pg/mL. 
19.5% 
 
  NA 
T, testosterone; PRL, prolactin; IRP, international reference preparation; fT4, free T4; ADH, anti-diuretic hormone; RT, room 
temperature; Rfg., refrigeration; Frz., freeze; NA, data not available; (a), Abbott Diagnostics, Chicago, IL; (b), Beckman Coulter, Brea, 
CA, USA; (c), Siemens Healthcare Diagnostics Inc., Tarrytown, NY; (d), Roche Diagnostics, Indianapolis, IN.; (e), Ortho-Clinical 
Diagnostics, Inc., Rochester, NY; Assay variability (imprecision) was calculated as 100x (standard deviation/ mean analyte 
concentration). Only assays with adequate available data are reviewed here. Variability was calculated using available data for the 
lowest analyte concentration. Raw variability data was obtained with permission from published BioRad Unity quality control data 
(Bio-Rad Laboratories I 9500 Jeronimo Road, Irvine, CA 92618). Information on sample stability was summarized from respective 
manufacturers’ published information. 
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